WO2023088425A1 - 15-pgdh抑制剂及用途 - Google Patents
15-pgdh抑制剂及用途 Download PDFInfo
- Publication number
- WO2023088425A1 WO2023088425A1 PCT/CN2022/132863 CN2022132863W WO2023088425A1 WO 2023088425 A1 WO2023088425 A1 WO 2023088425A1 CN 2022132863 W CN2022132863 W CN 2022132863W WO 2023088425 A1 WO2023088425 A1 WO 2023088425A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- group
- alkoxy
- halogenated
- optionally
- Prior art date
Links
- 108010051913 15-hydroxyprostaglandin dehydrogenase Proteins 0.000 title claims abstract description 43
- 239000003112 inhibitor Substances 0.000 title claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 184
- 150000003839 salts Chemical class 0.000 claims abstract description 61
- 150000002391 heterocyclic compounds Chemical group 0.000 claims abstract description 59
- 239000012453 solvate Substances 0.000 claims abstract description 49
- 102100030489 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Human genes 0.000 claims abstract description 41
- 239000000651 prodrug Substances 0.000 claims abstract description 26
- 229940002612 prodrug Drugs 0.000 claims abstract description 26
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 10
- -1 cyano, carbonyl Chemical group 0.000 claims description 142
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 114
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 89
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 84
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 82
- 229910052736 halogen Inorganic materials 0.000 claims description 65
- 150000002367 halogens Chemical class 0.000 claims description 65
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 62
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 58
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 51
- 201000010099 disease Diseases 0.000 claims description 49
- 125000004043 oxo group Chemical group O=* 0.000 claims description 47
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 44
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 42
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 42
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 42
- 229910052757 nitrogen Inorganic materials 0.000 claims description 42
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 42
- 125000001424 substituent group Chemical group 0.000 claims description 42
- 125000001425 triazolyl group Chemical group 0.000 claims description 42
- 238000012360 testing method Methods 0.000 claims description 40
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 38
- 125000005842 heteroatom Chemical group 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 239000001257 hydrogen Substances 0.000 claims description 34
- 125000006413 ring segment Chemical group 0.000 claims description 33
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 32
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 32
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 32
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 32
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims description 30
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 29
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 28
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 27
- 125000003277 amino group Chemical group 0.000 claims description 25
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 20
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 18
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 15
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 15
- 238000010829 isocratic elution Methods 0.000 claims description 15
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 208000027866 inflammatory disease Diseases 0.000 claims description 14
- 208000014674 injury Diseases 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 125000002950 monocyclic group Chemical group 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 238000006467 substitution reaction Methods 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 230000003176 fibrotic effect Effects 0.000 claims description 12
- 230000014759 maintenance of location Effects 0.000 claims description 12
- 230000000451 tissue damage Effects 0.000 claims description 12
- 231100000827 tissue damage Toxicity 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 101000652482 Homo sapiens TBC1 domain family member 8 Proteins 0.000 claims description 10
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 10
- 102100030302 TBC1 domain family member 8 Human genes 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000002619 bicyclic group Chemical group 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 10
- 230000006378 damage Effects 0.000 claims description 10
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 9
- 208000027418 Wounds and injury Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 8
- 210000004185 liver Anatomy 0.000 claims description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
- 230000008929 regeneration Effects 0.000 claims description 7
- 238000011069 regeneration method Methods 0.000 claims description 7
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- 125000003003 spiro group Chemical group 0.000 claims description 7
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- 230000004761 fibrosis Effects 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 5
- 206010067125 Liver injury Diseases 0.000 claims description 5
- 230000030833 cell death Effects 0.000 claims description 5
- 208000032625 disorder of ear Diseases 0.000 claims description 5
- 208000030533 eye disease Diseases 0.000 claims description 5
- 208000024908 graft versus host disease Diseases 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 5
- 230000004766 neurogenesis Effects 0.000 claims description 5
- 210000002569 neuron Anatomy 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 201000007094 prostatitis Diseases 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 208000029549 Muscle injury Diseases 0.000 claims description 4
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 238000010322 bone marrow transplantation Methods 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000003779 hair growth Effects 0.000 claims description 4
- 239000007943 implant Substances 0.000 claims description 4
- 208000004235 neutropenia Diseases 0.000 claims description 4
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 4
- 238000011476 stem cell transplantation Methods 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 208000011594 Autoinflammatory disease Diseases 0.000 claims description 3
- 206010028289 Muscle atrophy Diseases 0.000 claims description 3
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 3
- 208000025865 Ulcer Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 230000001093 anti-cancer Effects 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 125000002393 azetidinyl group Chemical group 0.000 claims description 3
- 210000000601 blood cell Anatomy 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 231100000234 hepatic damage Toxicity 0.000 claims description 3
- 230000008818 liver damage Effects 0.000 claims description 3
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 230000020763 muscle atrophy Effects 0.000 claims description 3
- 201000000585 muscular atrophy Diseases 0.000 claims description 3
- 201000006938 muscular dystrophy Diseases 0.000 claims description 3
- 208000011906 peptic ulcer disease Diseases 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 231100000397 ulcer Toxicity 0.000 claims description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 208000012639 Balance disease Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010011878 Deafness Diseases 0.000 claims description 2
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 2
- 206010013774 Dry eye Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 206010058914 Hypotonic urinary bladder Diseases 0.000 claims description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 206010028594 Myocardial fibrosis Diseases 0.000 claims description 2
- 208000000450 Pelvic Pain Diseases 0.000 claims description 2
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000033626 Renal failure acute Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims description 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 208000012886 Vertigo Diseases 0.000 claims description 2
- 201000011040 acute kidney failure Diseases 0.000 claims description 2
- 206010069351 acute lung injury Diseases 0.000 claims description 2
- 125000004442 acylamino group Chemical group 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 208000013507 chronic prostatitis Diseases 0.000 claims description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
- 239000002271 gyrase inhibitor Substances 0.000 claims description 2
- 230000010370 hearing loss Effects 0.000 claims description 2
- 231100000888 hearing loss Toxicity 0.000 claims description 2
- 208000016354 hearing loss disease Diseases 0.000 claims description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 231100000189 neurotoxic Toxicity 0.000 claims description 2
- 230000002887 neurotoxic effect Effects 0.000 claims description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 239000003865 nucleic acid synthesis inhibitor Substances 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 201000002793 renal fibrosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 230000003156 vasculitic effect Effects 0.000 claims description 2
- 231100000889 vertigo Toxicity 0.000 claims description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 3
- 208000037816 tissue injury Diseases 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 231100000753 hepatic injury Toxicity 0.000 claims 1
- 230000003836 peripheral circulation Effects 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 127
- 238000006243 chemical reaction Methods 0.000 description 63
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 56
- 239000012043 crude product Substances 0.000 description 56
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 55
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 55
- 239000000243 solution Substances 0.000 description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 54
- 238000002360 preparation method Methods 0.000 description 38
- 238000003786 synthesis reaction Methods 0.000 description 33
- 230000015572 biosynthetic process Effects 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 29
- 239000012071 phase Substances 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 238000005481 NMR spectroscopy Methods 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 25
- 239000012074 organic phase Substances 0.000 description 23
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 19
- 229910000024 caesium carbonate Inorganic materials 0.000 description 19
- 239000000543 intermediate Substances 0.000 description 19
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 18
- 150000002431 hydrogen Chemical class 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 239000003208 petroleum Substances 0.000 description 15
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 14
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 150000002430 hydrocarbons Chemical group 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- ZXMPSTMIJQZYLV-UHFFFAOYSA-N 2-methyl-1,2-dihydrophthalazin-1-one Chemical compound C1=CC=C2C(=O)N(C)N=CC2=C1 ZXMPSTMIJQZYLV-UHFFFAOYSA-N 0.000 description 5
- IBGHRWAYEACCDW-UHFFFAOYSA-N 3-methylpyrido[3,2-d]pyrimidin-4-one Chemical compound C1=CN=C2C(=O)N(C)C=NC2=C1 IBGHRWAYEACCDW-UHFFFAOYSA-N 0.000 description 5
- WRFZBWHXIGUNLQ-UHFFFAOYSA-N 5-bromo-2-methyl-3h-isoindol-1-one Chemical compound BrC1=CC=C2C(=O)N(C)CC2=C1 WRFZBWHXIGUNLQ-UHFFFAOYSA-N 0.000 description 5
- BSEWLITVJSOERI-UHFFFAOYSA-N 6-chloro-2-methyl-1H-pyrrolo[3,4-c]pyridin-3-one Chemical compound ClC1=CC2=C(C=N1)C(N(C2)C)=O BSEWLITVJSOERI-UHFFFAOYSA-N 0.000 description 5
- WFHBMNIKNOOHOP-UHFFFAOYSA-N 6-chloro-4-formylpyridine-3-carboxylic acid Chemical compound OC(=O)C1=CN=C(Cl)C=C1C=O WFHBMNIKNOOHOP-UHFFFAOYSA-N 0.000 description 5
- 239000012131 assay buffer Substances 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- CPWMCAMLRLHDAT-UHFFFAOYSA-N methyl 5-bromo-3-(bromomethyl)pyridine-2-carboxylate Chemical compound COC(=O)C1=NC=C(Br)C=C1CBr CPWMCAMLRLHDAT-UHFFFAOYSA-N 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- JNOVZPGBPRDTHN-UHFFFAOYSA-N (4-bromopyridin-2-yl)hydrazine Chemical compound NNC1=CC(Br)=CC=N1 JNOVZPGBPRDTHN-UHFFFAOYSA-N 0.000 description 4
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical compound C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 4
- 229960004378 nintedanib Drugs 0.000 description 4
- 125000006574 non-aromatic ring group Chemical group 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 2
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidine Chemical compound CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000009105 Short Chain Dehydrogenase-Reductases Human genes 0.000 description 2
- 108010048287 Short Chain Dehydrogenase-Reductases Proteins 0.000 description 2
- 208000004168 Underactive Urinary Bladder Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 210000005161 hepatic lobe Anatomy 0.000 description 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- CBFCDTFDPHXCNY-UHFFFAOYSA-N icosane Chemical compound CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- KZPOANNAYCXMSH-UHFFFAOYSA-N methyl 5-bromo-3-methylpyridine-2-carboxylate Chemical compound COC(=O)C1=NC=C(Br)C=C1C KZPOANNAYCXMSH-UHFFFAOYSA-N 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000010827 pathological analysis Methods 0.000 description 2
- 238000012335 pathological evaluation Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 2
- 210000000534 thyroid cartilage Anatomy 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- VJLYHTOSFSGXGH-CQSZACIVSA-N (2R)-1-[3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxybenzoyl]pyrrolidine-2-carboxylic acid Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)N2[C@H](CCC2)C(=O)O)C=CC=1 VJLYHTOSFSGXGH-CQSZACIVSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- XCFQIKQVRXAIEX-LURJTMIESA-N (3r)-3-(fluoromethyl)piperidine Chemical compound FC[C@@H]1CCCNC1 XCFQIKQVRXAIEX-LURJTMIESA-N 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- GKECDORWWXXNRY-UHFFFAOYSA-N 2h-pyridin-3-one Chemical compound O=C1CN=CC=C1 GKECDORWWXXNRY-UHFFFAOYSA-N 0.000 description 1
- UOGQPXQDNUHUIB-UHFFFAOYSA-N 3,3-difluoropiperidine Chemical compound FC1(F)CCCNC1 UOGQPXQDNUHUIB-UHFFFAOYSA-N 0.000 description 1
- KVTUSMPNLUCCQO-UHFFFAOYSA-N 3,3-difluoropyrrolidine Chemical compound FC1(F)CCNC1 KVTUSMPNLUCCQO-UHFFFAOYSA-N 0.000 description 1
- SAEGBAIURUCXRY-UHFFFAOYSA-N 3-(difluoromethyl)piperidine Chemical compound FC(F)C1CCCNC1 SAEGBAIURUCXRY-UHFFFAOYSA-N 0.000 description 1
- JOHFJTBDUSVGQB-UHFFFAOYSA-N 3-(trifluoromethyl)piperidine Chemical compound FC(F)(F)C1CCCNC1 JOHFJTBDUSVGQB-UHFFFAOYSA-N 0.000 description 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- WSNKEJIFARPOSQ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(1-benzothiophen-2-ylmethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC3=C(S2)C=CC=C3)C=CC=1 WSNKEJIFARPOSQ-UHFFFAOYSA-N 0.000 description 1
- MROVZCRMXJZHCN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-hydroxyethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCO)C=CC=1 MROVZCRMXJZHCN-UHFFFAOYSA-N 0.000 description 1
- SHBHYINHXNTBRP-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-methylsulfonylethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCS(=O)(=O)C)C=CC=1 SHBHYINHXNTBRP-UHFFFAOYSA-N 0.000 description 1
- VTNULXUEOJMRKZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2H-tetrazol-5-ylmethyl)benzamide Chemical compound N=1NN=NC=1CNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O VTNULXUEOJMRKZ-UHFFFAOYSA-N 0.000 description 1
- GDSLUYKCPYECNN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(4-fluorophenyl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC=C(C=C2)F)C=CC=1 GDSLUYKCPYECNN-UHFFFAOYSA-N 0.000 description 1
- ISXSUKUXUPLGTD-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(5-oxopyrrolidin-2-yl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2NC(CC2)=O)C=CC=1 ISXSUKUXUPLGTD-UHFFFAOYSA-N 0.000 description 1
- ZMCQQCBOZIGNRV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(1,2,4-triazol-1-yl)ethyl]benzamide Chemical compound NCC1=CC(OC2=CC=CC(=C2)C(=O)NCCN2C=NC=N2)=NC(=C1)C(F)(F)F ZMCQQCBOZIGNRV-UHFFFAOYSA-N 0.000 description 1
- AJZDHLHTTJRNQJ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(tetrazol-1-yl)ethyl]benzamide Chemical compound N1(N=NN=C1)CCNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O AJZDHLHTTJRNQJ-UHFFFAOYSA-N 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- HAEQAUJYNHQVHV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 HAEQAUJYNHQVHV-UHFFFAOYSA-N 0.000 description 1
- HGWUUOXXAIISDB-UHFFFAOYSA-N 3-azabicyclo[3.1.0]hexane Chemical compound C1NCC2CC21 HGWUUOXXAIISDB-UHFFFAOYSA-N 0.000 description 1
- BIAJIZVBOQVDTC-UHFFFAOYSA-N 3-bromo-6-methyl-5h-pyrrolo[3,4-b]pyridin-7-one Chemical compound BrC1=CN=C2C(=O)N(C)CC2=C1 BIAJIZVBOQVDTC-UHFFFAOYSA-N 0.000 description 1
- RDJUBLSLAULIAT-UHFFFAOYSA-N 3-fluoropiperidine;hydrochloride Chemical compound Cl.FC1CCCNC1 RDJUBLSLAULIAT-UHFFFAOYSA-N 0.000 description 1
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- MJOUJKDTBGXKIU-UHFFFAOYSA-N 4,4-difluoropiperidine Chemical compound FC1(F)CCNCC1 MJOUJKDTBGXKIU-UHFFFAOYSA-N 0.000 description 1
- BAJCFNRLEJHPTQ-UHFFFAOYSA-N 4-bromo-2-fluoro-n-methylbenzamide Chemical compound CNC(=O)C1=CC=C(Br)C=C1F BAJCFNRLEJHPTQ-UHFFFAOYSA-N 0.000 description 1
- PTPTZLXZHPPVKG-UHFFFAOYSA-N 4-bromo-2-fluoropyridine Chemical compound FC1=CC(Br)=CC=N1 PTPTZLXZHPPVKG-UHFFFAOYSA-N 0.000 description 1
- HQSCPPCMBMFJJN-UHFFFAOYSA-N 4-bromobenzonitrile Chemical compound BrC1=CC=C(C#N)C=C1 HQSCPPCMBMFJJN-UHFFFAOYSA-N 0.000 description 1
- OHYCXPXWHPWYFX-UHFFFAOYSA-N 5-bromo-n-methylpyridine-2-carboxamide Chemical compound CNC(=O)C1=CC=C(Br)C=N1 OHYCXPXWHPWYFX-UHFFFAOYSA-N 0.000 description 1
- UAWMVMPAYRWUFX-UHFFFAOYSA-N 6-Chloronicotinic acid Chemical compound OC(=O)C1=CC=C(Cl)N=C1 UAWMVMPAYRWUFX-UHFFFAOYSA-N 0.000 description 1
- GIBPTWPJEVCTGR-UHFFFAOYSA-N 6-azaspiro[2.5]octane Chemical compound C1CC11CCNCC1 GIBPTWPJEVCTGR-UHFFFAOYSA-N 0.000 description 1
- BCEWGGGNOQNYKK-UHFFFAOYSA-N 6-bromo-1h-1,8-naphthyridin-2-one Chemical compound N1C(=O)C=CC2=CC(Br)=CN=C21 BCEWGGGNOQNYKK-UHFFFAOYSA-N 0.000 description 1
- XWALISSRSGMCSU-UHFFFAOYSA-N 6-bromo-2-methylisoquinolin-1-one Chemical compound BrC1=CC=C2C(=O)N(C)C=CC2=C1 XWALISSRSGMCSU-UHFFFAOYSA-N 0.000 description 1
- FUGKKMYSCAYXJJ-UHFFFAOYSA-N 7-bromo-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C=2C1=CC(Br)=CC=2 FUGKKMYSCAYXJJ-UHFFFAOYSA-N 0.000 description 1
- MIUVFGIZCOBBGP-UHFFFAOYSA-N 7-bromo-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical compound N12C(=O)N(N=C1C=C(Br)C=C2)C MIUVFGIZCOBBGP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NRLQBVLOUUPAMI-UHFFFAOYSA-N 8-[3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxybenzoyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)N2CCC3(CNC(O3)=O)CC2)C=CC=1 NRLQBVLOUUPAMI-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 1
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 1
- YKKPYMXANSSQCA-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-(3-pyrazol-1-ylazetidin-1-yl)methanone Chemical compound N1(N=CC=C1)C1CN(C1)C(=O)C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F YKKPYMXANSSQCA-UHFFFAOYSA-N 0.000 description 1
- JOSCNYCOYXTLTN-GFCCVEGCSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R)-3-(hydroxymethyl)pyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@@H](CC1)CO JOSCNYCOYXTLTN-GFCCVEGCSA-N 0.000 description 1
- BYWBCSRCPLBDFU-CYBMUJFWSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R)-3-aminopyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@@H](CC1)N BYWBCSRCPLBDFU-CYBMUJFWSA-N 0.000 description 1
- LJHFUFVRZNYVMK-CYBMUJFWSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R)-3-hydroxypyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@@H](CC1)O LJHFUFVRZNYVMK-CYBMUJFWSA-N 0.000 description 1
- LJHFUFVRZNYVMK-ZDUSSCGKSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3S)-3-hydroxypyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@H](CC1)O LJHFUFVRZNYVMK-ZDUSSCGKSA-N 0.000 description 1
- JWSIZPAOIFLWKM-UHFFFAOYSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[3-(dimethylamino)-4-hydroxypyrrolidin-1-yl]methanone Chemical compound CN(C)C1CN(CC1O)C(=O)c1cccc(Oc2cc(CN)cc(n2)C(F)(F)F)c1 JWSIZPAOIFLWKM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- LKXYJYDRLBPHRS-UHFFFAOYSA-N bromocyclopropane Chemical compound BrC1CC1 LKXYJYDRLBPHRS-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 125000005345 deuteroalkyl group Chemical group 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
- 125000005049 dihydrooxadiazolyl group Chemical group O1N(NC=C1)* 0.000 description 1
- 125000005051 dihydropyrazinyl group Chemical group N1(CC=NC=C1)* 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 125000005058 dihydrotriazolyl group Chemical group N1(NNC=C1)* 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- HJLHTTJLVALHOP-UHFFFAOYSA-N hexane;hydron;chloride Chemical compound Cl.CCCCCC HJLHTTJLVALHOP-UHFFFAOYSA-N 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- SAISZWKSZYFSHS-UHFFFAOYSA-N methyl 1,8-naphthyridine-3-carboxylate Chemical compound COC(=O)C=1C=NC2=NC=CC=C2C1 SAISZWKSZYFSHS-UHFFFAOYSA-N 0.000 description 1
- SGFACFBLUAWICV-UHFFFAOYSA-N methyl 4-bromo-2-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=C(Br)C=C1CBr SGFACFBLUAWICV-UHFFFAOYSA-N 0.000 description 1
- 150000003956 methylamines Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000005961 oxazepanyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the invention belongs to the field of medicine, in particular, the invention relates to a 15-PGDH inhibitor and its application.
- the 15-hydroxyprostaglandin dehydrogenase (15-PGDH) gene is located on chromosome 4 4q34 ⁇ q35, with a span of about 31kb, a total of 7 exons, and a molecular weight of 29kD.
- 15-PGDH is composed of 266 amino acids and belongs to the family of short-chain dehydrogenases (SDR). It consists of two identical subunits to form a dimer, but some people think that it only has enzymatic activity when it exists as a monomer. .
- 15-PGDH is the key enzyme for the degradation and inactivation of prostaglandins (PGs) and related eicosane bioactive substances, and is widely present in the lungs, kidneys, gastrointestinal tract, thyroid, prostate and placenta of humans and mammals In normal tissues, on the one hand, it can catalyze the oxidation of active 15-hydroxy prostaglandins into 15-keto prostaglandins with greatly weakened activity; on the other hand, it can degrade some other non-prostaglandins in the presence of NAD + coenzyme factors
- the polycyclic aromatic hydrocarbons can reduce the carcinogens and pre-carcinogens produced under physiological or pathological conditions through oxidation reactions.
- the technical problem to be solved by the present invention is to overcome the defect in the prior art that there is no 15-PGDH inhibitory pathway to treat many diseases including fibrosis, and to provide a 15-PGDH inhibitor and its use.
- the compound of the present invention has a good inhibitory effect on 15-PGDH.
- the object of the present invention is to provide a new compound as a 15-PGDH inhibitor.
- Z 1 , Z 2 , Z 3 , Z 4 and Z 5 each independently represent a ring atom
- Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are each independently N, NH, O, S, CH 2 , CH or C;
- R 1 and R 2 are each independently hydrogen, C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl,
- R 1 and R 2 form a 3-11 membered heterocycloalkyl group together with the N atom to which they are attached; wherein, the 3-11 membered heterocycloalkyl group is further replaced by 0, 1 or more (such as 2 or 3) R 1-1 substituted; when there are multiple substituents, the substituents are the same or different;
- n are each independently 0, 1, 2 or 3;
- X 1 , X 2 , X 3 , X 4 and X 5 each independently represent a ring atom
- X 1 , X 2 , X 3 , X 4 and X 5 are each independently N, O, S, CH 2 , CH or C;
- the bond connected between X4 and X5 is a single bond or a double bond
- the group fragment formed by connecting X 4 and X 5 In, A does not exist, or A and X 4 , X 5 ring atoms together form a 3-11 membered heterocycloalkyl, 5 membered heteroaryl ring or 6 membered heteroaryl ring; the heteroatoms are independently selected from N, O and One or more of S;
- X4 and X5 are each independently replaced by R4 or R5 ;
- the A is further substituted by R 3-1 ;
- the R 3-1 is substituted with one or more substitutions, and when there are multiple substituents, the substituents are the same or different;
- Z 1 , Z 2 , Z 3 , Z 4 and Z 5 each independently represent a ring atom
- Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are each independently N or C;
- R 1 and R 2 are each independently hydrogen, C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl;
- R 1 and R 2 form a 3-11 membered heterocycloalkyl group together with the N atom to which they are attached; wherein, the C 3 -C 8 cycloalkyl group or 3-11 membered heterocycloalkyl group is further replaced by R 1 -1 is replaced by;
- n are each independently 0, 1, 2 or 3;
- X 1 , X 2 , X 3 , X 4 and X 5 each independently represent a ring atom
- X 1 , X 2 , X 3 , X 4 and X 5 are each independently N or C;
- the group fragment formed by connecting X 4 and X 5 In, A does not exist, or A and X 4 , X 5 ring atoms together form a 3-11 membered heterocycloalkyl, 5-membered heteroaryl ring or 6-membered heteroaryl ring; the heteroatom is selected from N, O, S one or more;
- X4 and X5 are each independently replaced by R4 or R5 ;
- the A is further substituted by R 3-1 ;
- the R 3-1 is substituted with one or more substitutions, and when there are multiple substituents, the substituents are the same or different;
- the heteroatoms in the above-mentioned 3-11 membered heterocycloalkyl, 5-membered heteroaryl ring and 6-membered heteroaryl ring are one or more of N, O or S, each The number is 1, 2, 3 or 4.
- the number of heteroatoms is 1, the heteroatoms are selected from N and O, and the 6-membered heteroalkane ring substituted by cyclopropane" or “the number of heteroatoms is 1, and the heteroatoms are selected from N.
- the 6-membered heteroalkane ring substituted by cyclopropane Heteroalkane ring such as pyridine ring.
- the heterocyclic compound represented by formula I has a structure represented by formula I-1 or a structure represented by formula I-2:
- the solvate is a hydrate.
- said R 1 and R 2 together with the N atom to which they are connected form a 3-11 membered heterocycloalkyl group in which the heterocycloalkyl group is a monocyclic heterocycloalkyl group, bridged ring A bicyclic heterocycloalkyl or a spiro bicyclic heterocycloalkyl.
- the R 1 and R 2 together with the N atom they are connected to form a 3-11 membered heterocycloalkyl.
- the heteroatom in the heterocycloalkyl is one or more of N, O or S , the number is 1, 2, 3 or 4.
- said R 1 and R 2 together with the N atom to which they are connected form a 3-11 membered heterocycloalkyl group which is further substituted by one or more R 1-1 .
- said R 1 and R 2 together with the N atom to which they are attached form a 3-8 membered heterocycloalkyl group.
- the 3-8 membered heterocycloalkyl is a monocyclic 3-8 membered heterocycloalkyl, a condensed bicyclic 3-8 membered heterocycloalkyl, or optionally includes a bridged ring or a spiro ring Bicyclic 3-8 membered heterocycloalkyl.
- the 3-8 membered heterocycloalkyl group further has 1 to 3 heteroatoms selected from one or more of N, O and S.
- the 3-8 membered heterocycloalkyl is further substituted by halogen or halogenated C 1 -C 6 alkyl, or, the 3-8 membered heterocycloalkyl is further substituted by halogen and/or halogen C 1 -C 6 alkyl substituted.
- the 3-8 membered heterocycloalkyl is a monocyclic 3-6 membered heterocycloalkyl, a bridged bicyclic 6-8 membered heterocycloalkyl or a spirocyclic bicyclic 8 Membered heterocycloalkyl, heteroatoms are N and/or O, the number is 1 or 2, such as azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, pyrrolidinocyclopropyl , azaspiro[2.5]octyl, azaspiro[2.5]octyl, or octahydrocyclopenta[c]pyrrolidinyl.
- the 3-8 membered heterocycloalkyl group is further substituted by a C 1 -C 6 alkyl group.
- the number of substitutions is 0, 1, 2 or 3.
- the halogen and the halogen in the halogenated C 1 -C 6 alkyl are each independently F, Cl or Br, such as F.
- the C 1 -C 6 alkyl in the C 1 -C 6 alkyl and the C 1 -C 6 alkyl in the halogenated C 1 -C 6 alkyl are each independently methyl radical, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, for example methyl.
- the halogenated C 1 -C 6 alkyl is trifluoromethyl, difluoromethyl or monofluoromethyl (for example ).
- R and R together with the N atom to which they are attached form the following group:
- R and R together with the N atom to which they are attached form the following group:
- the halogens are each independently F, Cl or Br, such as F.
- the C 1 -C 6 alkyl groups in the aminocarbonyl group optionally having 1 or 2 C 1 -C 6 alkyl groups are independently is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, for example methyl.
- the aminocarbonyl groups optionally having 1 or 2 C 1 -C 6 alkyl groups are each independently
- said A together with X 4 and X 5 ring atoms form a 3-11 membered heterocycloalkyl group in which the heterocycloalkyl group is a monocyclic cycloalkyl group or a spirocyclic bicyclic group heterocycloalkyl.
- said A and X 4 , X 5 ring atoms together form a 3-11 membered heterocycloalkyl group.
- the number of heteroatoms in the heterocycloalkyl group is 1, 2, 3 or 4.
- said A and X 4 , X 5 ring atoms together form a 3-11 membered heterocycloalkyl group in which the 3-11 membered heterocycloalkyl group is a 3-7 membered heterocycloalkyl group .
- said A together with X 4 and X 5 ring atoms form a 3-11 membered heterocycloalkyl group in which the 3-11 membered heterocycloalkyl group is a monocyclic 3-6 membered heterocycloalkyl group.
- the number of heteroatoms in the 5-membered heteroaryl ring or 6-membered heteroaryl ring formed by A and X 4 , X 5 ring atoms is 1, 2, 3 or 4 .
- said A and X 4 , X 5 ring atoms together form a 5-membered heteroaryl ring or a 6-membered heteroaryl ring.
- the heteroatoms in the 6-membered heteroaryl ring are N, and the number is 1, 2 or 3 , such as pyridine ring, pyrimidine ring or triazole ring.
- the halogen in the halogenated C 1 -C 6 alkyl is F, Cl or Br, such as F.
- the C 1 -C 6 alkyl, the halogenated C 1 -C 6 alkyl and the C 1 -C 6 deuterated alkane are each independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, such as methyl or ethyl .
- the halogenated C 1 -C 6 alkyl is
- the C 1 -C 6 deuterated alkyl is -CD 3 .
- the cycloalkyl in the C 3 -C 8 cycloalkyl is a monocyclic cycloalkyl.
- the cycloalkyl group in the C 3 -C 8 cycloalkyl group is cyclopropyl group, cyclobutanyl group, cyclopentyl group or cyclohexyl group.
- Z 1 , Z 2 and Z 3 are each independently N, CH or C.
- Z 4 and Z 5 are each independently N, NH, CH 2 or CH.
- R 1 and R 2 form a 3-11 membered heterocycloalkyl group together with the N atom to which they are attached; wherein, the 3-11 membered heterocycloalkyl group is further replaced by 0, 1 One or more R 1-1 substituted.
- R 1-1 is halogen, C 1 -C 6 alkyl or halogenated C 1 -C 6 alkyl.
- R 4 and R 5 are independently halogen, cyano or an aminocarbonyl group optionally having 1 or 2 C 1 -C 6 alkyl groups.
- Z 1 , Z 2 and Z 3 are each independently N or C;
- Z 4 and Z 5 are each independently N, NH, CH 2 or CH;
- R 1 and R 2 together form a 3-11 membered heterocycloalkyl group with the N atom they are connected to; wherein, the 3-11 membered heterocycloalkyl group is further replaced by 0, 1 or more R 1-1 replace;
- R 1-1 is halogen, C 1 -C 6 alkyl or halogenated C 1 -C 6 alkyl
- R3 is hydrogen
- R 4 and R 5 are independently halogen, cyano or an aminocarbonyl group optionally having 1 or 2 C 1 -C 6 alkyl groups;
- heterocyclic compound shown in formula I is selected from the following structures:
- heterocyclic compound shown in formula I is selected from the following structures:
- X 4 and X 5 each independently represent a ring atom; X 4 and X 5 are each independently N or C; A together with X 4 and X 5 form a 3-8 membered heterocycloalkyl group, and the 3-8
- heterocyclic compound shown in formula I is selected from the following structures:
- heterocyclic compound shown in formula I is selected from the following structures:
- heterocyclic compound shown in formula I is selected from the following structures:
- R3 is H, halogen, hydroxyl, amino, nitro, cyano, carbonyl, oxo, carboxyl, C 1 -C 6 alkyl, C 1 -C 6 deuterated alkyl, C 2 -C 6 alkyne Base, halogenated C 1 -C 6 alkyl, hydroxy C 1 -C 6 alkyl, C 1 -C 6 alkylcarbonyl, C 1 -C 6 alkoxy, halogenated C 1 -C 6 alkoxy;
- Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R a , R b , m and n are as defined in the first aspect of the present invention.
- heterocyclic compound shown in formula I is selected from the following structures:
- Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 3-1 , R a , R b , m and n are as defined in the first described in the aspect.
- heterocyclic compound shown in formula I is selected from the following structures:
- Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 3-1 , R a , R b , m and n are as defined in the first described in the aspect.
- heterocyclic compound shown in formula I is selected from the following structures:
- Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 3-1 , R a , R b , m and n are as defined in the first described in the aspect.
- heterocyclic compound shown in formula I is selected from the following structures:
- Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 3-1 , R a , R b , m and n are as defined in the first described in the aspect.
- heterocyclic compound shown in formula I is selected from the following structures:
- Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 3-1 , R a , R b , m and n are as defined in the first described in the aspect.
- heterocyclic compound shown in formula I is selected from the following structures:
- Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 3-1 , R a , R b , m and n are as defined in the first described in the aspect.
- heterocyclic compound shown in formula I is selected from the following structures:
- Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 3-1 , R a , R b , m and n are as defined in the first described in the aspect.
- heterocyclic compound shown in formula I is selected from the following structures:
- Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 3-1 , R a , R b , m and n are as defined in the first described in the aspect.
- heterocyclic compound shown in formula I is selected from the following structures:
- Z 1 , Z 2 , Z 3 , X 1 , X 2 , X 3 , R 1 , R 2 , R 3 , R 3-1 , R a , R b , m and n are as defined in the first described in the aspect.
- heterocyclic compound shown in formula I is selected from the following structures:
- heterocyclic compound shown in formula I is selected from the following structures:
- heterocyclic compound shown in formula I is selected from the following structures:
- heterocyclic compound shown in formula I is selected from the following structures:
- heterocyclic compound represented by formula I is selected from any of the following compounds:
- heterocyclic compound represented by formula I is selected from any of the following compounds:
- heterocyclic compound represented by formula I is selected from any of the following compounds:
- Isocratic elution 50% by volume of a solution of isopropanol and acetonitrile containing 0.05% by volume of diethylamine in CO 2 , flow rate: 3mL/min; detector: PDA, column temperature: 35°C; column pressure: 100Bar;
- the retention time is 1.670min
- Isocratic elution 50% by volume of a solution of isopropanol and acetonitrile containing 0.05% by volume of diethylamine in CO 2 , flow rate: 3mL/min; detector: PDA, column temperature: 35°C; column pressure: 100Bar;
- the retention time is 0.816min
- Chromatographic column Chiralpak AS-3 50 ⁇ 4.6mm ID, 3 ⁇ m;
- Mobile phase mobile phase A: CO 2
- mobile phase B a solution of isopropanol and acetonitrile containing 0.05% by volume of diethylamine;
- isocratic elution A solution of 40% by volume of isopropanol and acetonitrile containing 0.05% by volume of diethylamine in CO 2 ; flow rate: 3mL/min; detector: PDA, column temperature: 35°C; column pressure: 100Bar;
- Chromatographic column Chiralpak AS-3 50 ⁇ 4.6mm ID, 3 ⁇ m;
- Mobile phase mobile phase A: CO 2
- mobile phase B a solution of isopropanol and acetonitrile containing 0.05% by volume of diethylamine;
- isocratic elution A solution of 40% by volume of isopropanol and acetonitrile containing 0.05% by volume of diethylamine in CO 2 ; flow rate: 3mL/min; detector: PDA, column temperature: 35°C; column pressure: 100Bar;
- Chromatographic column Chiralpak AD-3 50 ⁇ 4.6mm ID, 3 ⁇ m
- mobile phase mobile phase A: CO 2
- mobile phase B a solution of isopropanol and acetonitrile containing 0.05% by volume of diethylamine
- isocratic elution A solution of 50% by volume of isopropanol and acetonitrile containing 0.05% by volume of diethylamine in CO 2 , flow rate: 3mL/min
- detector PDA, column temperature: 35°C
- column pressure 100Bar;
- Chromatographic column Chiralpak AD-3 50 ⁇ 4.6mm ID, 3 ⁇ m
- mobile phase mobile phase A: CO 2
- mobile phase B a solution of isopropanol and acetonitrile containing 0.05% by volume of diethylamine
- isocratic elution 50% by volume solution of isopropanol and acetonitrile containing 0.05% by volume of diethylamine in CO 2 , flow rate: 3 mL/min
- detector PDA
- column temperature 35° C.
- column pressure 100 Bar.
- heterocyclic compound represented by formula I is selected from any of the following compounds:
- IC 50 is 12.16nM
- IC 50 is 3.58nM
- IC 50 1.52nM
- IC 50 7.42nM
- IC 50 is 3.78nM
- heterocyclic compound represented by formula I is selected from any of the following compounds:
- the multiple that increases under the test condition of embodiment 2 is 0.9
- the multiple that increases under the test condition of embodiment 2 is 4.8
- the multiple that increases under the test condition of embodiment 2 is 0.9
- the For the pulmonary fibrosis total score is 3.34 under the test condition of embodiment 3
- Cmax is 4480ng/mL
- the For AUC (0-t) is 33173h ⁇ ng/mL under the test condition of embodiment 5
- the third aspect of the present invention provides a pharmaceutical composition, said pharmaceutical composition comprising: the compound represented by formula I as described in the first aspect of the present invention, its solvate, its pharmaceutically acceptable salt, its A solvate of a pharmaceutically acceptable salt or a prodrug thereof; and a pharmaceutically acceptable carrier.
- the fourth aspect of the present invention provides the compound represented by formula I as described in the first aspect of the present invention, its solvate, its pharmaceutically acceptable salt, its pharmaceutically acceptable salt's solvate or its precursor
- the use of medicine, or the use of the pharmaceutical composition described in the fifth aspect of the present invention includes: inhibiting 15-PGDH; and/or, preventing and/or treating 15-PGDH-related diseases; and/or, as 15-PGDH inhibitors, and/or preparing medicines, pharmaceutical compositions or preparations for preventing and/or treating 15-PGDH-related diseases.
- the 15-PGDH-related diseases include but are not limited to: fibrotic diseases, inflammatory diseases, cardiovascular diseases, trauma, autoimmune diseases, graft-versus-host disease, hair growth, osteoporosis, Ear disease, eye disease, neutropenia, diabetes, underactive bladder, implant promotion in stem cell or bone marrow transplantation or organ transplantation, neurogenesis and nerve cell death, blood cell reconstitution, tissue damage, cervical disease, and kidney disease one, two or more.
- the 15-PGDH-related diseases include but are not limited to: fibrotic diseases, inflammatory diseases, cardiovascular diseases, trauma, autoimmune diseases, graft-versus-host disease, hair growth, osteoporosis, Ear disease, eye disease, neutropenia, diabetes, underactive bladder, implant promotion in stem cell or bone marrow transplantation or organ transplantation, neurogenesis and nerve cell death, blood cell reconstitution, tissue damage, cervical disease, and kidney disease one, two or more.
- the 15-PGDH-related diseases include but are not limited to: fibrotic diseases (such as pulmonary fibrosis, including idiopathic pulmonary fibrosis, etc., liver fibrosis, renal fibrosis, myocardial fibrosis, scleroderma and myelofibrosis), inflammatory diseases (such as chronic obstructive pulmonary disease (COPD), acute lung injury, sepsis, exacerbation of asthma and lung disease, inflammatory bowel disease (IBD) (such as ulcerative colitis and Crohn's disease), peptic ulcer (such as NSAID-induced ulcer), autoinflammatory disease (such as Behcet's disease), vasculitic syndrome, acute liver injury, acute kidney injury, nonalcoholic fatty liver disease (NASH), Atopic dermatitis, psoriasis, interstitial cystitis, prostatitis syndrome (eg, chronic prostatitis/chronic pelvic pain syndrome)], cardiovascular disease (eg, pulmonary hypertension,
- the tissue damage is liver damage and/or muscle damage (such as muscle atrophy and muscular dystrophy).
- the 15-PGDH-related diseases include but not limited to: idiopathic pulmonary fibrosis (IPF).
- IPF idiopathic pulmonary fibrosis
- the prevention and/or treatment of 15-PGDH-related diseases includes but not limited to: liver regeneration.
- the 15-PGDH-related diseases include but not limited to: liver damage.
- the 15-PGDH-related diseases include but not limited to: IBD.
- the use described is for the preparation of medicaments for preventing or treating the following diseases; the diseases are one or more of fibrotic diseases, inflammatory diseases or tissue damage.
- the fibrotic disease, the inflammatory disease and the tissue damage can all be the same as those mentioned above.
- a method for inhibiting 15-PGDH, or preventing and/or treating 15-PGDH-related diseases comprising the steps of: administering the formula I described in the first aspect of the present invention to a subject in need A compound, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of a pharmaceutically acceptable salt thereof, or a prodrug thereof.
- the diseases related to 15-PGDH are the same as those mentioned above.
- a method for preventing or treating diseases comprising the step of: administering the compound represented by formula I described in the first aspect of the present invention, its solvate, and its pharmaceutically acceptable salt to a subject in need , a solvate of a pharmaceutically acceptable salt thereof or a prodrug thereof; the disease is one or more of fibrotic diseases, inflammatory diseases or tissue damage.
- Both the fibrotic disease and the inflammatory disease can be the same as above.
- reactions and purifications can be carried out using the manufacturer's instructions for the kit, or by methods known in the art or as described herein.
- the techniques and methods described above can generally be performed according to conventional methods well known in the art as described in various general and more specific documents that are cited and discussed in this specification.
- groups and substituents thereof can be selected by those skilled in the art to provide stable moieties and compounds.
- substituents When a substituent is described by a conventional chemical formula written from left to right, the substituent also includes chemically equivalent substituents obtained when the structural formula is written from right to left. For example, CH2O is equivalent to OCH2 .
- R 1 ", “R1” and “R 1 " have the same meaning and can be substituted for each other. For other symbols such as R 2 , similar definitions have the same meanings.
- a number from 1 to 10 should be understood as not only recording each integer of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, but also at least recording each of the integers with The sum of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9; for example, 1 to 3 is to be understood as 1, 2 and 3.
- halogen alone or as part of another substituent, means fluorine, chlorine, bromine, iodine; preferably fluorine or chlorine.
- alkyl means consisting solely of carbon and hydrogen atoms, free of unsaturated bonds, having, for example, 1 to 6 carbon atoms and attached to the rest of the molecule by a single bond straight-chain or branched hydrocarbon chain groups.
- alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, and hexyl.
- alkenyl means an unbranched or branched monovalent hydrocarbon chain containing one or more carbon-carbon double bonds.
- alkynyl refers to an unbranched or branched monovalent hydrocarbon chain containing one or more carbon-carbon triple bonds.
- C 1 -C 6 alkyl alone or as part of another substituent is understood to mean a linear or branched saturated monovalent hydrocarbon radical having 1, 2, 3, 4, 5 or 6 carbon atoms.
- the alkyl group is for example methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl Base, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3
- cycloalkyl by itself or as part of another substituent means a cyclic alkyl group.
- mn-membered cycloalkyl or " Cm - Cncycloalkyl” is understood to mean a saturated carbocyclic ring having m to n atoms.
- 3-15 membered cycloalkyl or “C 3 -C 15 cycloalkyl” refers to a cyclic alkyl group containing 3 to 15, 3 to 9, 3 to 6 or 3 to 5 carbon atoms, which May contain 1 to 4 rings.
- 3-10 membered cycloalkyl contains 3-10 carbon atoms.
- cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and adamantyl, or a bicyclic hydrocarbon group such as a decahydronaphthalene ring.
- cycloalkyl is used interchangeably with the term "carbocyclyl”.
- heterocycloalkyl by itself or as part of another substituent refers to a cycloalkyl group in which one or more (in some embodiments, 1 to 3) carbon atoms are replaced by a heteroatom which Atoms are such as, but not limited to, N, O, S, and P.
- mn membered heterocycloalkyl or "C m -C n heterocycloalkyl” is understood to mean a saturated ring having m to n atoms, wherein the hetero ring atoms are selected from N, O, S, P, Preferably selected from N, O or S.
- the term "4-8 membered heterocycloalkyl” or “C 4 -C 8 heterocycloalkyl” is understood to mean a saturated ring having 4 to 8 ring atoms, wherein 1, 2, 3, or 4 ring atoms are selected from N, O, S, P, preferably selected from N, O or S.
- "4-10 membered heterocyclyl” means a saturated ring having 4 to 10 ring atoms. When a prefix such as 4-8 membered or 4-10 membered is used to indicate heterocycloalkyl, the number of carbons is also meant to include heteroatoms. Including monocyclic, bicyclic, tricyclic, spiro or bridged rings.
- heterocycloalkyl groups are: pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydropyridyl, tetrahydropyrrolyl, azetidinyl, thiazolidinyl, oxazolidinyl , piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, azepanyl, diazepanyl, oxazepanyl, etc.
- heterocycloalkyl is used interchangeably with the term “heteroalkane”.
- alkenyl by itself or as part of another substituent refers to a straight or branched chain monovalent hydrocarbon group of two to forty carbon atoms having at least one carbon-carbon sp2 double bond (for example C2- C 6 alkenyl, another example is C 2 -C 4 alkenyl), and includes groups with "cis” and “trans” orientations or "E” and “Z” orientations.
- alkenyl groups include, but are not limited to, vinyl and allyl.
- alkynyl by itself or as part of another substituent refers to a straight or branched chain monovalent hydrocarbon radical (e.g. C2 - C6 ) of two to forty carbon atoms having at least one carbon-carbon sp triple bond.
- alkynyl another example is C 2 -C 4 alkynyl).
- alkynyl include, but are not limited to, ethynyl and propynyl.
- alkoxy by itself or as part of another substituent, refers to the group -ORx , wherein Rx is "alkyl" as defined above.
- oxo by itself or as part of another substituent, means that two hydrogens on a methylene group are replaced by oxygen, ie a methylene group is replaced by a carbonyl group.
- aryl by itself or as part of another substituent means a monocyclic or polycyclic carbocyclic ring having from 6 to 20 carbon atoms, at least one of which is aromatic. When one of the rings is a non-aromatic ring, the group can be attached through an aromatic ring or through a non-aromatic ring. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthrenyl, anthracenyl, and acenaphthyl.
- heteromatic ring means a monocyclic or polycyclic carbocyclic ring in which at least one ring atom is a heteroatom independently selected from oxygen, sulfur and nitrogen, and the remaining ring atoms are C, wherein at least one ring is aromatic.
- the group may be a carbon group or a heteroatom group (ie it may be C-attached or N-attached, wherever this is possible).
- the group can be attached through an aromatic ring or through a non-aromatic ring.
- heteroaryl groups include, but are not limited to: imidazolyl, acridinyl, carbazolyl, cinnolinyl, quinoxalinyl, pyrazolyl, indolyl, benzotriazolyl, furyl, thienyl, Benzothienyl, benzofuryl, quinolinyl, isoquinolyl, oxazolyl, isoxazolyl, indolyl, pyrazinyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, N - methylpyrrolyl and tetrahydroquinoline.
- heteroaryl may be used interchangeably with the terms “heteroaromatic", “heteroaryl” or "heteroaryl”.
- heteroalkene ring refers to a monocyclic group with heteroatoms (the monocyclic group has a double bond, but is not aromatic), preferably containing 1, 2 or a monocyclic ring of 3 ring heteroatoms independently selected from N, O and S.
- heterocycloalkenyl groups are: dihydrofuryl, dihydrothienyl, dihydropyrrolyl, dioxolyl, dihydroimidazolyl, dihydropyrazolyl, dihydrothiazolyl, dihydroiso Thiazolyl, dihydrooxadiazolyl, dihydrothiadiazolyl, dihydrotriazolyl, dihydrotetrazolyl, tetrahydropyridyl, 3,4-dihydro-2H-pyran, pyranyl, Thipyryl, dihydropyridyl, dihydropyrazinyl, dihydropyrimidinyl, oxazinyl, dihydrotetrazolyl and the like.
- heteroalkenyl may be used interchangeably with the term “heterocycloalkenyl”.
- the term "spiro" refers to a polycyclic group in which the single rings share one carbon atom (called the spiro atom), which may contain one or more double bonds, but none of the rings has A fully conjugated ⁇ -electron system.
- the spirocycloalkyl can be divided into single spirocycloalkyl, double spirocycloalkyl or polyspirocycloalkyl, preferably single spirocycloalkyl and double spirocycloalkyl.
- Non-limiting examples of spirocycloalkyl groups include:
- spirocycloalkyls in which a single spirocycloalkyl shares a spiro atom with a heterocycloalkyl, non-limiting examples include:
- bridged ring refers to a cyclic hydrocarbon in which any two rings in a compound share two carbon atoms that are not directly connected, and can be divided into bicyclic hydrocarbons, tricyclic hydrocarbons, tetracyclic hydrocarbons, etc.
- Non-limiting examples include:
- haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2,2,2-trifluoroethyl, heptafluoropropyl, and heptachloropropyl.
- Deuteroalkyl by itself or as part of another substituent means an alkyl group substituted with one or more deuterium atoms, wherein alkyl is as defined above.
- salt or “pharmaceutically acceptable salt” includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
- pharmaceutically acceptable refers to those compounds, materials, compositions and/or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with human and animal tissues without excessive Toxicity, irritation, allergic reaction, or other problems or complications, commensurate with a reasonable benefit/risk ratio.
- “Pharmaceutically acceptable acid addition salt” refers to a salt formed with an inorganic or organic acid that retains the biological effectiveness of the free base without other side effects.
- “Pharmaceutically acceptable base addition salt” refers to a salt formed with an inorganic base or an organic base that can maintain the biological effectiveness of the free acid without other side effects.
- other salts are contemplated by the present invention. They may serve as intermediates in the purification of compounds or in the preparation of other pharmaceutically acceptable salts or may be useful in the identification, characterization or purification of compounds of the invention.
- solvate means that the compound of the present invention or its salt includes a stoichiometric or non-stoichiometric solvent bonded by intermolecular non-covalent forces, and when the solvent is water, it is a hydrate.
- solvate of a pharmaceutically acceptable salt refers to a substance formed by combining a compound with a pharmaceutically acceptable acid, base, or solvent (including but not limited to: water, methanol, ethanol, etc.). Wherein, the amount of solvent can be stoichiometric or non-stoichiometric. Solvates of pharmaceutically acceptable salts include, but are not limited to, monohydrochloride monohydrate.
- prodrug refers to a compound of the invention that can be converted to biological activity under physiological conditions or by solvolysis.
- the prodrugs of the present invention are prepared by modifying functional groups in the compounds which can be removed routinely or in vivo to yield the parent compound.
- Prodrugs include compounds formed by linking a hydroxyl or amino group in the compound of the present invention to any group. When the prodrug of the compound of the present invention is administered to a mammalian individual, the prodrug is split to form free hydroxyl, free of amino.
- a "pharmaceutical composition” refers to a formulation of a compound of the present invention with a vehicle generally accepted in the art for the delivery of a biologically active compound to a mammal (eg, a human).
- the medium includes a pharmaceutically acceptable carrier.
- the purpose of the pharmaceutical composition is to promote the administration of the organism, facilitate the absorption of the active ingredient and thus exert its biological activity.
- pharmaceutically acceptable carrier includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener approved by the relevant government regulatory agency as acceptable for human or livestock use , diluent, preservative, dye/colorant, flavoring agent, surfactant, wetting agent, dispersing agent, suspending agent, stabilizing agent, isotonic agent, solvent or emulsifying agent.
- excipient refers to a pharmaceutically acceptable inert ingredient.
- examples of categories of the term “excipient” include, but are not limited to, binders, disintegrants, lubricants, glidants, stabilizers, fillers, diluents, and the like. Excipients can enhance the handling characteristics of a pharmaceutical formulation, ie make the formulation more suitable for direct compression by increasing flow and/or cohesiveness.
- treatment refers to therapeutic therapy.
- treatment means: (1) amelioration of one or more biological manifestations of the disease or condition, (2) interference with (a) one or more points in the biological cascade leading to or causing the condition or (b ) one or more biological manifestations of the disorder, (3) amelioration of one or more symptoms, effects or side effects associated with the disorder, or one or more symptoms, effects or side effects associated with the disorder or its treatment, Or (4) slowing the development of the disorder or one or more biological manifestations of the disorder.
- prevention refers to a reduction in the risk of acquiring or developing a disease or disorder.
- patient refers to any animal, preferably a mammal, that is about to or has received the administration of the compound or composition according to the embodiments of the present invention.
- mammal includes any mammal. Examples of mammals include, but are not limited to, cows, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc., preferably humans.
- terapéuticaally effective amount refers to an amount of a compound which, when administered to a patient, is sufficient to effectively treat a disease or condition described herein.
- the “therapeutically effective amount” will vary depending on the compound, the disorder and its severity, and the age of the patient to be treated, and can be adjusted as necessary by those skilled in the art.
- inflammatory bowel disease refers to IBD and is used to describe diseases involving chronic inflammation of the digestive tract.
- the main types include: ulcerative colitis and Crohn's disease. Ulcerative colitis. Causes inflammation and ulcers in the superficial lining of the large intestine (colon) and rectum. Crohn's disease, on the other hand, is characterized by inflammation of the lining of the digestive tract, often involving the deeper layers of the digestive tract.
- the reaction temperature can be appropriately selected according to the solvent, starting material, reagent, etc.
- the reaction time can also be appropriately selected according to the reaction temperature, solvent, starting material, reagent, etc.
- the target compound can be separated and purified from the reaction system according to common methods, such as filtration, extraction, recrystallization, washing, silica gel column chromatography and other methods. Without affecting the next step reaction, the target compound can also directly enter the next step reaction without separation and purification.
- the positive and progressive effect of the present invention is that: the inventor has unexpectedly developed a heterocyclic compound or a pharmaceutically acceptable salt thereof, a preparation method and use thereof after extensive and in-depth research.
- the compound represented by formula I of the present invention has at least one of the following effect advantages;
- the present invention provides the compound shown in formula I, its solvate, its pharmaceutically acceptable salt, the solvate of its pharmaceutically acceptable salt or its prodrug, described formula I compound is right to 15-PGDH Has a significant inhibitory effect;
- the present invention provides methods and intermediates for preparing the compound shown in I, its solvate, its pharmaceutically acceptable salt, its solvate of its pharmaceutically acceptable salt or its prodrug, and the method operation
- the method is simple, high in yield and high in purity, and can be used in the industrialized production of medicines.
- Fig. 1 is each group animal pulmonary fibrosis scoring figure in the IPF prevention model drug effect experiment of test example 3 of the present invention; Sham operation (Sham), "#" means p ⁇ 0.05vs.G2 model group.
- Fig. 2 is the score diagram of pulmonary fibrosis of each group of animals in the IPF treatment model drug effect experiment of Test Example 4 of the present invention; wherein, "***” means p ⁇ 0.001vs.G1-Sham; T-test: "#” means p ⁇ 0.05 vs. model group; “##” means p ⁇ 0.01 vs. model group.
- Fig. 3 is the DAI scoring diagram of each group of Test Example 7 of the present invention; wherein, "***" indicates p ⁇ 0.001 vs. the G2 model control group.
- Fig. 4 is each group intestinal weight/intestinal length/body mass index figure of test example 7 of the present invention. Wherein, adopt single factor analysis of variance (One-way ANOVA): "***" represents p ⁇ 0.001vs.G2 model control group .
- Fig. 5 is the colonic injury score diagram of each group of Test Example 7 of the present invention; wherein, "***” indicates p ⁇ 0.001vs.G2 model control group, and “**” indicates p ⁇ 0.01vs.G2 model control group.
- Figure 6 is a score chart of colonic inflammatory cell infiltration in each group of Test Example 7 of the present invention; wherein, "***" indicates p ⁇ 0.001vs.G2 model control group, and “*” indicates p ⁇ 0.05vs.G2 model control group .
- IC 50 half inhibitory concentration, which refers to the concentration at which half of the maximum inhibitory effect is achieved
- n-butyllithium 14.56mL, 29.1mmol, 2.5M n-hexane solution
- the first step the synthesis of 5-bromo-2-methylisoindolin-1-one (A1-2)
- methyl 4-bromo-2-(bromomethyl)benzoate (1 g, 3.26 mmol) was added to 2M methylamine (1.95 ml, 3.9 mmol) and triethylamine (0.9 ml, 6.52 mmol) of the mixture was heated at 100 °C for 12 h. After the reaction was completed, the mixture was concentrated under reduced pressure. The resulting residue was diluted with ethyl acetate and washed with water. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was triturated with hexane to give 5-bromo-2-methylisoindolin-1-one (500 mg, yield 68%).
- intermediate A2 refers to the synthesis of intermediate A1, and deuterated methylamine is used instead of methylamine.
- the first step the synthesis of methyl 5-bromo-3-(bromomethyl)pyridine-2-carboxylate (A3-2)
- 5-Bromo-3-methylpyridine-2-carboxylic acid methyl ester (A3-1) (5g, 21.73mmol) was dissolved in carbon tetrachloride (50mL), and azobisisobutyronitrile (0.71g, 4.35 mmol) and NBS (4.64g, 26.1mmol), reacted at 80°C for 5h.
- the second step the synthesis of 3-bromo-6-methyl-5,6-dihydro-7H-pyrrole[3,4-b]pyridin-7-one (A3-3)
- methyl 5-bromo-3-(bromomethyl)pyridine-2-carboxylate (1 g, 3.24 mmol) was added to 2M methylamine (1.95 ml, 3.9 mmol) and triethylamine ( 0.9ml, 6.52mmol) of the mixture was heated at 100°C for 12h. After the reaction was completed, the mixture was concentrated under reduced pressure. The resulting residue was diluted with ethyl acetate and washed with water. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was triturated with hexane to give 3-bromo-6-methyl-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one (500 mg, yield 68%).
- Step 3 Synthesis of 3'-bromo-6'-methylspiro[cyclopropane-1,5'-pyrrole[3,4-b]pyridine]-7'(6'H)-one (A3)
- the first step Synthesis of 6-bromo-1-(4-methoxybenzyl)-1,8-naphthyridin-2(1H)-one (B1-2)
- 6-bromo-3-(4-methoxybenzyl)-1,1a,3,7b-tetrahydro-2H-cyclopropane[c][1,8]naphthyridin-2-one 500mg, 1.39mmol
- tetrahydrofuran 4mL
- borane dimethyl sulfide solution 10M, 1.39mL, 13.9mmol
- Step 4 Methyl 3-(4-methoxybenzyl)-1a,2,3,7b-tetrahydro-1H-cyclopropane[c][1,8]naphthyridine-6-carboxylate (B1 -5) Synthesis
- the seventh step (4,4-difluoropiperidin-1-yl)(1a,2,3,7b-tetrahydro-1H-cyclopropane[c][1,8]naphthyridin-6-yl)methanol Synthesis of Ketones (B1-8)
- the eighth step 5-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropane[c][1,8]naphthyridine- 3-yl)-2-methylisoindolin-1-one (I-1)
- the first step 4-bromo-2-hydrazinopyridine (B3-2)
- the third step 7-bromo-2-methyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (B3-4)
- the fourth step 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropane[c][1,8]naphthyridine- 3-yl)-2-methyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (I-3)
- Isocratic elution 50vol% IPA+ACN (0.05vol% DEA) in CO 2 , flow rate: 3mL/min; detector: PDA, column temperature: 35°C; column pressure: 100Bar).
- the first step 7-bromo-2-cyclopropyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (B4-1)
- the synthetic route of target compound 1-5 is as follows:
- Example 6 6'-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropane[c][1,8]naphthyridine Preparation of -3-yl)-2'-(deuteromethyl)spiro[cyclopropane-1,1'-isoindoline]-3'-one (I-6)
- Example 7 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropane[c][1,8]naphthyridine- 3-yl)-2-(2,2,2-trifluoroethyl)-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (I-7) preparation of
- the synthetic route of target compound 1-7 is as follows:
- the synthetic route of target compound 1-8 is as follows:
- the synthetic route of target compound 1-10 is as follows:
- the synthetic route of target compound 1-12 is as follows:
- the synthetic route of target compound 1-13 is as follows:
- the synthetic route of target compound 1-14 is as follows:
- the synthetic route of target compound 1-15 is as follows:
- compound I-15 refers to compound I-1
- the intermediate B15-1 is used to replace A1-2
- the synthesis of intermediate B15-1 refers to patent WO2021016333.
- the synthetic route of target compound 1-16 is as follows:
- the synthetic route of target compound 1-17 is as follows:
- the synthetic route of target compound 1-18 is as follows:
- the first step the synthesis of 6-chloro-4-formyl nicotinic acid (B18-2)
- the third step 6-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropane[c][1,8]naphthyridine- Synthesis of 3-yl)-2-methyl-1,2-dihydro-3H-pyrrole[3,4-c]pyridin-3-one (I-18)
- the synthesis of compound I-18 refers to the synthesis of compound I-1, and intermediate B18-3 is used instead of A1-2.
- the synthetic route of target compound 1-19 is as follows:
- Example 20 7-(6-(3-fluoro-3-methylazetidine-1-carbonyl)-1a,2-dihydro-1H-cyclopropeno[c][1,8]naphthyridine- Preparation of 3(7bH)-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-20)
- the synthetic route of target compound 1-20 is as follows:
- Step 1 Methyl 1a,2,3,7b-tetrahydro-1H-cyclopropane[c][1,8]naphthyridine-6-carboxylate (B20-1)
- the second step 3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolyl[4,3-a]pyridin-7-yl)-1a, Methyl 2,3,7b-tetrahydro-1H-cyclopropane[c][1,8]naphthyridine-6-carboxylate (B20-2)
- the third step 3-(2-methyl-3-oxo-2,3-dihydro-[1,2,4]triazolyl[4,3-a]pyridin-7-yl)-1a, 2,3,7b-tetrahydro-1H-cyclopropane[c][1,8]naphthyridine-6-carboxylic acid (B20-3)
- the fourth step 7-(6-(3-fluoro-3-methylazetidine-1-carbonyl)-1a,2-dihydro-1H-cyclopropeno[c][1,8]naphthyridine- 3(7bH)-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-20)
- the synthetic route of target compound 1-22 is as follows:
- Example 23 7-(6-(3-(Difluoromethyl)piperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropane[c][1,8]naphthalene Preparation of pyridin-3-yl)-2-methyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-23)
- the synthetic route of target compound 1-24 is as follows:
- the synthetic route of target compound 1-25 is as follows:
- Product I-25 was resolved by SFC (column: Chiralpak AD-3 50 ⁇ 4.6mm ID, 3 ⁇ m, mobile phase: mobile phase A: CO 2 , mobile phase B: IPA+ACN (0.05 vol% DEA); isocratic Elution: 50 vol% IPA+ACN (0.05 vol% DEA) (in CO 2 ), flow rate: 3 mL/min; detector: PDA, column temperature: 35° C.; column pressure: 100 Bar).
- Example 27 7-(6-(3-fluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropane[c][1,8]naphthyridin-3-yl Preparation of )-2-methyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (I-27)
- Example 29 7-(6-(3-Azabicyclo[3.1.0]hexane-3-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropane[c][1,8 Preparation of ]naphthyridin-3-yl)-2-methyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (I-29)
- the synthetic route of target compound 1-30 is as follows:
- Example 32 7-(6-(4,4-Difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropane[c][1,8]naphthyridine- Preparation of 3-yl)-2-ethyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (I-32)
- the first step Synthesis of 7-bromo-2-ethyl-[1,2,4]triazolyl[4,3-a]pyridin-3(2H)-one (B32-1)
- the second step 7-(6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropane[c][1,8]naphthyridine- Synthesis of 3-yl)-2-ethyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one (I-32)
- reaction solution was poured into water (10 mL), extracted with ethyl acetate (10 mL ⁇ 3), the organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product.
- Test Example 1 Compound Inhibition Test on 15-PGDH Enzyme
- Assay Buffer 50 mM Tris-HCl, pH 7.5, 0.01 vol% Tween 20 was used to prepare 15-PGDH (R&D Systems, Cat. No. 5660-DH-010) to twice the final concentration, ie 30 nM. Then, 8 ⁇ l/well was added to a 384 white plate (Cisbio Bioassays, Cat. No. 66PL384025). Set negative control wells, add only Assay Buffer without enzyme. Then use Assay Buffer to configure the compound to 4 times the final concentration, that is, start at 4000nM, dilute 3 times, and have 10 concentrations.
- Test Example 2 Effects of Compounds on PGE 2 Levels in A549 Cell Supernatant
- A549 cells (Wuhan Punuosai) were cultured in F12K+10% FBS, and the cells in good logarithmic phase were taken for experiments, the cells were digested, counted, and the cells were seeded into 24-well plates, 8000 cells/well. The cells were cultured overnight in a 37°C, 5% CO 2 incubator. After the cells adhere to the wall, change the medium containing 0.5% FBS for about 10 hours, add IL-1 ⁇ to each well (final concentration 20ng/mL, 1mL/well), and set up a control group (the control group does not add IL-1 ⁇ ) .
- Test Example 3 Drug efficacy experiment of mouse IPF prevention model
- mice Male mice were adaptively fed for 1-2 weeks, and after reaching the standard body weight (25g), a certain dose of bleomycin was used to induce the IPF model (idiopathic pulmonary fibrosis model).
- the animals On the day of modeling, the animals were randomly divided into models according to their weight. group and administration group, wherein the administration group is administration of nintedanib (60mg/kg, administered once a day (qd)) and administration of compound I-3B of the present invention (2.5mg/kg, twice a day (bid)), and began oral gavage administration every day, and the vehicle control group was given blank vehicle for 21 consecutive days.
- body weight was measured every 3 days.
- the animals were euthanized, and the lungs were removed from the thyroid cartilage (without perfusion), and 10% formalin was slowly perfused into the lungs until the bilateral lungs were filled, and the main trachea was ligated and placed 5-10 times
- the tissue volume was fixed in 10% formalin, and the left lung was made into paraffin tissue sections, HE stained and Masson Trichrome stained, and a Hamamatsu NanoZoomer Digital Pathology (S210) slice scanner was used for panoramic scanning of the slices for pathological analysis.
- S210 Hamamatsu NanoZoomer Digital Pathology
- Test Example 4 Drug efficacy experiment of mouse IPF treatment model
- mice Male mice were adaptively fed for 1-2 weeks, and after reaching the standard body weight (25g), a certain dose of bleomycin was used to induce the IPF model (idiopathic pulmonary fibrosis model).
- the animals were randomly divided into models according to their weight. group and administration group, wherein the administration group is administration of nintedanib (60mg/kg, qd), low dose administration of compound I-3B of the present invention (1mg/kg, bid) and high dose administration of the present invention
- the compound I-3B (2.5mg/kg, bid) was orally administered by gavage every day from Day 7, and the vehicle control group was given blank vehicle for 14 consecutive days. During the dosing period, body weight was measured twice a week.
- the animals were euthanized, and the lungs were removed from the thyroid cartilage (without perfusion), and 10% formalin was slowly perfused into the lungs until the bilateral lungs were filled, and the main trachea was ligated and placed 5-10 times
- the tissue volume was fixed in 10% formalin, and the left lung was made into paraffin tissue sections, HE stained and Masson Trichrome stained, and a Hamamatsu NanoZoomer Digital Pathology (S210) slice scanner was used for panoramic scanning of the slices for pathological analysis.
- S210 Hamamatsu NanoZoomer Digital Pathology
- Test Example 5 Drug effect experiment of mouse liver resection regeneration
- mice pharmacokinetic properties of the compounds of the present invention were determined according to the following experimental methods.
- mice Female C57BL/6 mice aged 6-8 weeks were divided into 5 groups, G1-G5 were normal control group, model control group, positive control group, compound I-3B low-dose group and compound I-3B high-dose group.
- CW intestinal weight
- CL intestinal length
- BW intestinal tissue
- the test results showed that, compared with the G2 model group animals, the G3-positive control group (cyclosporin CsA 25mg/kg-qd) significantly increased the body weight of the animals, the DAI of the model animals decreased significantly, the CL increased significantly, and the CW, CL/CW/ BW and CL/CW were significantly reduced, and the histopathological examination results of the colon of model animals showed inflammatory cell infiltration and decreased tissue damage scores, but there was no significant difference.
- the G3-positive control group cyclosporin CsA 25mg/kg-qd
- G4-compound I-3B (2.5mg/kg-bid), G5-compound I-3B (5mg/kg-bid) group animals all increased, wherein G5 animal body weight increased significantly; animal DAI all significantly decreased, CL CW, CL/CW/BW, and CL/CW were all significantly decreased; colon histopathological examination results showed that inflammatory cell infiltration and tissue damage scores were significantly decreased.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
化合物编号 | IC 50(nM) |
化合物I-1 | 4.3 |
化合物I-2 | 5.15 |
化合物I-19 | 3.72 |
化合物I-3 | 4.2 |
化合物I-3A | 12.16 |
化合物I-3B | 3.58 |
化合物I-9 | 9.51 |
化合物I-11 | 3.8 |
化合物I-12 | 2.1 |
化合物I-12A | 1.52 |
化合物I-12B | 7.42 |
化合物I-13 | 4.03 |
化合物I-14 | 8.6 |
化合物I-15 | 5.7 |
化合物I-16 | 5.4 |
化合物I-17 | 4.5 |
化合物I-18 | 19.98 |
化合物I-25 | 2.59 |
化合物I-25A | 15.8 |
化合物I-25B | 3.78 |
化合物I-20 | 2.83 |
化合物I-21 | 4.95 |
化合物I-22 | 10.17 |
化合物I-23 | 4.26 |
化合物I-24 | 4.23 |
化合物I-26 | 9.9 |
化合物I-27 | 5.7 |
化合物I-28 | 1.71 |
化合物I-29 | 5.3 |
化合物I-30 | 6.0 |
化合物I-31 | 4.1 |
化合物I-32 | 6.3 |
化合物编号/浓度 | 20nM |
化合物I-1 | 4.3 |
化合物I-2 | 5.23 |
化合物I-19 | 4.72 |
化合物I-3A | 0.9 |
化合物I-3B | 4.8 |
化合物I-11 | 1.88 |
化合物I-12 | 5.44 |
化合物I-13 | 6.1 |
化合物I-14 | 2.3 |
化合物I-15 | 3.7 |
化合物I-16 | 3.7 |
化合物I-17 | 2.2 |
化合物I-25A | 0.9 |
化合物I-25B | 4.4 |
化合物I-20 | 2.0 |
化合物I-21 | 2.3 |
化合物I-23 | 2.93 |
化合物I-24 | 2.95 |
化合物I-26 | 4.82 |
化合物I-27 | 2.60 |
化合物I-28 | 4.05 |
化合物I-29 | 2.3 |
化合物I-30 | 2.72 |
化合物I-31 | 2.90 |
化合物I-32 | 3.7 |
组别 | 肺纤维化总评分 |
G1假手术组(sham) | 0 |
G2模型组 | 4.69 |
G3尼达尼布 | 3.39 |
化合物I-3B | 3.34 |
组别 | 肺纤维化总评分 |
G1sham | 0 |
G2模型组 | 3.68 |
G3尼达尼布 | 2.84 |
G4化合物I-3B低剂量组 | 2.74 |
G4化合物I-3B高剂量组 | 2.6 |
化合物编号 | C max(ng/mL) | AUC (0-t)(h·ng/mL) |
化合物I-3 | 3710 | 35502 |
化合物I-3B | 4480 | 33173 |
化合物I-12 | 14800 | 107087 |
化合物I-25 | 3710 | 35771 |
化合物I-28 | 5040 | 10661 |
Claims (15)
- 一种式I所示杂环类化合物、其溶剂化物、其药学上可接受的盐、其药学上可接受的盐的溶剂合物或其前药:其中,Z 1、Z 2、Z 3、Z 4和Z 5各自独立地表示环原子;Z 1、Z 2、Z 3、Z 4和Z 5各自独立地为N、NH、O、S、CH 2、CH或C;R 1和R 2各自独立地为氢、C 1-C 6烷基或C 3-C 8环烷基,或者,R 1和R 2与其所连接到的N原子一起形成3-11元杂环烷基;其中,所述3-11元杂环烷基进一步被0个、1个或多个R 1-1所取代;当取代基为多个时,所述的取代基相同或不同;各R 1-1各自独立地为卤素、羟基、氨基、硝基、氰基、羰基、氧代、羧基、C 1-C 6烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基、卤代C 1-C 6烷氧基、C 1-C 6烷氧羰基、C 1-C 6烷基羰氧基、C 1-C 6烷氧基C 1-C 6烷基、C 1-C 6烷氧羰基C 1-C 6烷基、C 3-C 8环烷基、C 3-C 8环烷基羰基、C 3-C 8环烷氧基、任选具有1或2个C 1-C 6烷基基团的氨基羰基基团、C 1-C 6烷基磺酰基基团、任选具有1或2个C 1-C 6烷基基团的氨基磺酰基、C 1-C 6烷基磺酰基氨基基团或任选具有1或2个C 1-C 6烷基基团的氨基;R a和R b各自独立地为卤素、羟基、氨基、硝基、氰基、羰基、氧代、羧基、C 1-C 6烷基、C 1-C 6氘代烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基或卤代C 1-C 6烷氧基;m和n各自独立地为0、1、2或3;X 1、X 2、X 3、X 4和X 5各自独立地表示环原子;X 1、X 2、X 3、X 4和X 5各自独立地为N、O、S、CH 2、CH或C;X 4与X 5之间所连接的键为单键或双键;R 3为氢、卤素、羟基、氨基、硝基、氰基、羰基、氧代、羧基、C 1-C 6烷基、C 1-C 6氘代烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基、卤代C 1-C 6烷氧基、C 1-C 6烷氧羰基、C 1-C 6烷氧基C 1-C 6烷基、C 1-C 6烷氧羰基C 1-C 6烷基、C 3-C 8环烷基、C 3-C 8环烷基羰基、 C 3-C 8环烷氧基、任选具有1或2个C 1-C 6烷基基团的氨基羰基基团、C 1-C 6烷基磺酰基基团、任选具有1或2个C 1-C 6烷基基团的氨基磺酰基、C 1-C 6烷基磺酰基氨基基团或任选具有1或2个C 1-C 6烷基基团的氨基;当A不存在时,X 4和X 5各自独立地被R 4或R 5所取代;当A存在时,所述A进一步被R 3-1所取代;所述的R 3-1取代为一个或多个取代,当取代基为多个时,所述的取代基相同或不同;R 4和R 3-1各自独立地为氢、卤素、羟基、氨基、硝基、氰基、羰基、氧代、羧基、C 1-C 6烷基、C 1-C 6氘代烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基、卤代C 1-C 6烷氧基、C 1-C 6烷氧羰基、C 1-C 6烷基羰氧基、C 1-C 6烷氧基C 1-C 6烷基、C 1-C 6烷氧羰基C 1-C 6烷基、C 3-C 8环烷基、C 3-C 8环烷基羰基、C 3-C 8环烷氧基、任选具有1或2个C 1-C 6烷基基团的氨基羰基基团、C 1-C 6烷基磺酰基基团、任选具有1或2个C 1-C 6烷基基团的氨基磺酰基、C 1-C 6烷基磺酰基氨基基团或任选具有1或2个C 1-C 6烷基基团的氨基;R 5为氢、卤素、羟基、氨基、硝基、氰基、羰基、氧代、羧基、C 1-C 6烷基、C 1-C 6氘代烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基、卤代C 1-C 6烷氧基、C 1-C 6烷氧羰基、C 1-C 6烷基羰氧基、C 1-C 6烷氧基C 1-C 6烷基、C 1-C 6烷氧羰基C 1-C 6烷基、C 3-C 8环烷基、C 3-C 8环烷基羰基、C 3-C 8环烷氧基、任选具有1或2个R 5-1取代的氨基羰基基团、C 1-C 6烷基磺酰基基团、任选具有1或2个C 1-C 6烷基基团的氨基磺酰基、C 1-C 6烷基磺酰基氨基基团或任选具有1或2个C 1-C 6烷基基团的氨基;所述各R 5-1各自独立地为氢、卤素、羟基、氨基、硝基、氰基、羰基、氧代、羧基、C 1-C 6烷基、C 1-C 6氘代烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基、卤代C 1-C 6烷氧基、C 1-C 6烷氧羰基、C 1-C 6烷基羰氧基、C 1-C 6烷氧基C 1-C 6烷基、C 1-C 6烷氧羰基C 1-C 6烷基、C 3-C 8环烷基、C 3-C 8环烷基羰基、C 3-C 8环烷氧基、C 1-C 6烷基磺酰基基团、任选具有1或2个C 1-C 6烷基基团的氨基磺酰基、C 1-C 6烷基磺酰基氨基基团或任选具有1或2个C 1-C 6烷基基团的氨基。
- 如权利要求1所述的式I所示杂环类化合物、其溶剂化物、其药学上可接受的盐、其药学上可接受的盐的溶剂合物或其前药,其特征在于,所述的式I所示杂环类化合物满足如下1个或多个条件:(1)所述R 1和R 2与其所连接到的N原子一起形成3-11元杂环烷基中的杂环烷基为单环的杂环烷基、桥环的二环的杂环烷基或螺环的二环的杂环烷基;(2)所述R 1和R 2与其所连接到的N原子一起形成3-11元杂环烷基中的杂原子为N、O或S中的一种或多种,个数为1、2、3或4个;(3)所述R 1和R 2与其所连接到的N原子一起形成3-11元杂环烷基中的3-11元杂环烷基为3-8 元杂环烷基;(4)R 1-1中,所述卤素和所述卤代C 1-C 6烷基中的卤素和卤各自独立地为F、Cl或Br,例如F;(5)R 1-1中,所述C 1-C 6烷基和所述卤代C 1-C 6烷基中的C 1-C 6烷基各自独立地为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基,例如甲基;(6)R 4和R 5中,所述卤素各自独立地为F、Cl或Br,例如F;(7)R 4和R 5中,所述任选具有1或2个C 1-C 6烷基基团的氨基羰基基团中C 1-C 6烷基各自独立地为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基,例如甲基;(8)所述的A与X 4、X 5环原子一起形成3-11元杂环烷基中的杂环烷基为单环的杂环烷基或螺环的二环的杂环烷基;(9)所述的A与X 4、X 5环原子一起形成3-11元杂环烷基中的3-11元杂环烷基为3-7元杂环烷基;(10)所述的A与X 4、X 5环原子一起形成3-11元杂环烷基中的杂环烷基中的杂原子的个数为1、2、3或4个;(11)所述的A与X 4、X 5环原子一起形成5元杂芳环或6元杂芳环中的杂原子的个数为1、2、3或4个;(12)当A存在时,所述的A进一步被R 3-1所取代时,所述的R 3-1个数为2个;(13)R 3-1中,所述的卤代C 1-C 6烷基中的卤为F、Cl或Br,例如F;(14)R 3-1中,所述的C 1-C 6烷基、所述的卤代C 1-C 6烷基和所述的C 1-C 6氘代烷基中的C 1-C 6烷基各自独立地为甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基或叔丁基,例如甲基或乙基;(15)R 3-1中,所述的C 3-C 8环烷基中环烷基为单环的环烷基;(16)R 3-1中,所述的C 3-C 8环烷基中环烷基为环丙烷基、环丁烷基、环戊烷基或环己烷基;
- 如权利要求2所述的式I所示杂环类化合物、其溶剂化物、其药学上可接受的盐、其药学上可接受的盐的溶剂合物或其前药,其特征在于,所述的式I所示杂环类化合物满足如下1个或多个条件:(1)所述3-8元杂环烷基为单环的3-6元杂环烷基、桥环二环的6-8元杂环烷基或螺环的二环的8元杂环烷基,杂原子为N和/或O,个数为1或2个,例如氮杂环丁烷基、吡咯烷基、哌啶基、吗啡啉基、吡咯烷基并环丙基、氮氧杂螺环[2.5]辛烷基、氮杂螺环[2.5]辛烷基或八氢环戊并[c]吡咯烷基;(2)所述3-8元杂环烷基进一步被卤素和/或卤代C 1-C 6烷基所取代;(5)所述的A与X 4、X 5环原子一起形成3-11元杂环烷基中的3-11元杂环烷基为单环的3-6元杂环烷基或螺环的二环的7元杂环烷基,杂原子独立地为N和/或O,个数为1、2或3个,例如吡咯烷基或氮杂螺环[2.4]庚烷基;(6)所述的A与X 4、X 5环原子一起形成5元杂芳环或6元杂芳环中的杂原子为N,个数为1、2或3个,例如吡啶环、嘧啶环或三氮唑环;(8)R 3-1中,所述的C 1-C 6氘代烷基为-CD 3;
- 如权利要求1所述的式I所示杂环类化合物、其溶剂化物、其药学上可接受的盐、其药学上可接受的盐的溶剂合物或其前药,其特征在于,所述的式I所示杂环类化合物满足如下1个或多个条件:(1)Z 1、Z 2和Z 3各自独立地为N、CH或C;(2)Z 4和Z 5各自独立地为N、NH、CH 2或CH;(3)R 1和R 2与其所连接到的N原子一起形成3-11元杂环烷基;其中,所述3-11元杂环烷基进一步被0个、1个或多个R 1-1所取代;(4)R 1-1为卤素、C 1-C 6烷基或卤代C 1-C 6烷基;(5)R 4和R 5独立为卤素、氰基或任选具有1或2个C 1-C 6烷基基团的氨基羰基基团;(6)R 3-1独立地为氧代、C 1-C 6烷基、卤代C 1-C 6烷基、C 3-C 8环烷基或C 1-C 6氘代烷基;(7)所述的式I所示杂环类化合物药学上可接受的盐的溶剂合物为水合物;(8)所述的式I所示的杂环类化合物具有式I-1所示结构或式I-2所示结构:
- 如权利要求1-5中任一项所述的式I所示杂环类化合物、其溶剂化物、其药学上可接受的盐、其药学上可接受的盐的溶剂合物或其前药,其特征在于,所述的式I所示杂环类化合物为如下任一方案:方案1:所述的式I所示杂环类化合物为式I'所示化合物:式I'中,Z 1、Z 2、Z 3、Z 4和Z 5各自独立地表示环原子;Z 1、Z 2、Z 3、Z 4和Z 5各自独立地为N或C;R 1和R 2各自独立地为氢、C 1-C 6烷基或C 3-C 8环烷基;或者,R 1和R 2与其所连接到的N原子一起形成3-11元杂环烷基;其中,所述C 3-C 8环烷基或3-11元杂环烷基进一步被R 1-1所取代;各R 1-1各自独立地为卤素、羟基、氨基、硝基、氰基、羰基、氧代(=O)、羧基、C 1-C 6烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基、卤代C 1-C 6烷氧基、C 1-C 6烷氧羰基、C 1-C 6烷氧基C 1-C 6烷基、C 1-C 6烷氧羰基C 1-C 6烷基、C 3-C 8环烷基、C 3-C 8环烷基羰基、C 3-C 8环烷氧基、任选具有1或2个C 1-C 6烷基基团的氨基羰基基团、C 1-C 6烷基磺酰基基团、任选具有1或2个C 1-C 6烷基基团的氨基磺酰基、C 1-C 6烷基磺酰基氨基基团或任选具有1或2个C 1-C 6烷基基团的氨基;R a和R b各自独立地为卤素、羟基、氨基、硝基、氰基、羰基、氧代(=O)、羧基、C 1-C 6烷基、C 1-C 6氘代烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基或卤代C 1-C 6烷氧基;m和n各自独立地为0、1、2或3;X 1、X 2、X 3、X 4和X 5各自独立地表示环原子;X 1、X 2、X 3、X 4和X 5各自独立地为N或C;R 3为卤素、羟基、氨基、硝基、氰基、羰基、氧代(=O)、羧基、C 1-C 6烷基、C 1-C 6氘代烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基或卤代C 1-C 6烷氧基;当A不存在时,X 4和X 5各自独立地被R 4或R 5所取代;当A存在时,所述A进一步被R 3-1所取代;所述的R 3-1取代为一个或多个取代,当取代基为多个时,所述的取代基相同或不同;R 4、R 5和R 3-1各自独立地为氢、卤素、羟基、氨基、硝基、氰基、羰基、氧代(=O)、羧基、C 1-C 6烷基、C 1-C 6氘代烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基、卤代C 1-C 6烷氧基、C 1-C 6烷氧羰基、C 1-C 6烷氧基C 1-C 6烷基、C 1-C 6烷氧羰基C 1-C 6烷基、C 3-C 8环烷基、C 3-C 8环烷基羰基、C 3-C 8环烷氧基、任选具有1或2个C 1-C 6烷基基团的氨基羰基基团、C 1-C 6烷基磺酰基基团、任选具有1或2个C 1-C 6烷基基团的氨基磺酰基、C 1-C 6烷基磺酰基氨基基团或任选具有1或2个C 1-C 6烷基基团的氨基方案2:所述的式I所示杂环类化合物中:Z 1、Z 2和Z 3各自独立地为N或C;Z 4和Z 5各自独立地为N、NH、CH 2或CH;R 1和R 2与其所连接到的N原子一起形成3-11元杂环烷基;其中,所述3-11元杂环烷基进一步被0个、1个或多个R 1-1所取代;R 1-1为卤素、C 1-C 6烷基或卤代C 1-C 6烷基;m和n为0;R 3为氢;R 4和R 5独立为卤素、氰基或任选具有1或2个C 1-C 6烷基基团的氨基羰基基团;R 3-1独立地为氧代、C 1-C 6烷基、卤代C 1-C 6烷基、C 3-C 8环烷基或C 1-C 6氘代烷基;方案3:所述的如式I所示的杂环类化合物为如下如式II-1所示结构:式II-1中各基团的定义为如下情形3-1或情形3-2:情形3-1:X 4和X 5各自独立地表示环原子;X 4和X 5各自独立地为N、CH或C;A与X 4、X 5一起形成3-8元杂环烷基,所述3-8元杂环烷基进一步被R 3-1所取代;所述的R 3-1取代为一个或多个取代,当取代基为多个时,所述的取代基相同或不同;各R 3-1各自独立地为氢、卤素、羟基、氨基、硝基、氰基、羰基、氧代、羧基、C 1-C 6烷基、C 1-C 6氘代烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基、卤代C 1-C 6烷氧基、C 1-C 6烷氧羰基、C 1-C 6烷基羰氧基、C 1-C 6烷氧基C 1-C 6烷基、C 1-C 6烷氧羰基C 1-C 6烷基、C 3-C 8环烷基、C 3-C 8环烷基羰基、C 3-C 8环烷氧基、任选具有1或2个C 1-C 6烷基基团的氨基羰基基团、C 1-C 6烷基磺酰基基团、任选具有1或2个C 1-C 6烷基基团的氨基磺酰基、C 1-C 6烷基磺酰基氨基基团或任选具有1或2个C 1-C 6烷基基团的氨基;Z 1、Z 2、Z 3、X 1、X 2、X 3、R 1、R 2、R 3、R a、R b、m和n的定义如权利要求1所述;情形3-2:X 4和X 5各自独立地表示环原子;X 4和X 5各自独立地为N或C;A与X 4、X 5一起形成3-8元杂环烷基,所述3-8元杂环烷基进一步被R 3-1所取代;所述的R 3-1取代为一个或多个取代,当取代基为多个时,所述的取代基相同或不同;各R 3-1各自独立地为氢、卤素、羟基、氨基、硝基、氰基、羰基、氧代、羧基、C 1-C 6烷基、C 1-C 6氘代烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基、卤代C 1-C 6烷氧基、C 1-C 6烷氧羰基、C 1-C 6烷氧基C 1-C 6烷基、C 1-C 6烷氧羰基C 1-C 6烷基、C 3-C 8环烷基、C 3-C 8环烷基羰基、C 3-C 8环烷氧基、任选具有1或2个C 1-C 6烷基基团的氨基羰基基团、C 1-C 6烷基磺酰基基团、任选具有1或2个C 1-C 6烷基基团的氨基磺酰基、C 1-C 6烷基磺酰基氨基基团或任选具有1或2个C 1-C 6烷基基团的氨基;Z 1、Z 2、Z 3、X 1、X 2、X 3、R 1、R 2、R 3、R a、R b、m和n的定义如权利要求1所述;方案4:所述的如式I所示的杂环类化合物为如下如式II-2所示结构:式II-2中各基团的定义为如下情形4-1或情形4-2:情形4-1:R 3、R 4和R 5各自独立地选自氢、卤素、羟基、氨基、硝基、氰基、羰基、氧代、羧基、C 1-C 6烷基、C 1-C 6氘代烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基、卤代C 1-C 6烷氧基、C 1-C 6烷氧羰基、C 1-C 6烷氧基C 1-C 6烷基、C 1-C 6烷氧羰基C 1-C 6烷基、C 3-C 8环烷基、C 3-C 8环烷基羰基、C 3-C 8环烷氧基、任选具有1或2个C 1-C 6烷基基团的氨基羰基基团、C 1-C 6烷基磺酰基基团、任选具有1或2个C 1-C 6烷基基团的氨基磺酰基、C 1-C 6烷基磺酰基氨基基团和任选具有1或2个C 1-C 6烷基基团的氨基;Z 1、Z 2、Z 3、X 1、X 2、X 3、R 1、R 2、R a、R b、m和n的定义如权利要求1所述;情形4-2:R 3为卤素、羟基、氨基、硝基、氰基、羰基、氧代、羧基、C 1-C 6烷基、C 1-C 6氘代烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基、卤代C 1-C 6烷氧基;R 4和R 5各自独立地为氢、卤素、羟基、氨基、硝基、氰基、羰基、氧代、羧基、C 1-C 6烷基、C 1-C 6氘代烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基、卤代C 1-C 6烷氧基、C 1-C 6烷氧羰基、C 1-C 6烷基羰氧基、C 1-C 6烷氧基C 1-C 6烷基、C 1-C 6烷氧羰基C 1-C 6烷基、C 3-C 8环烷基、C 3-C 8环烷基羰基、C 3-C 8环烷氧基、任选具有1或2个C 1-C 6烷基基团的氨基羰基基团、C 1-C 6烷基磺酰基基团、任选具有1或2个C 1-C 6烷基基团的氨基磺酰基、C 1-C 6烷基磺酰基氨基基团或任选具有1或2个C 1-C 6烷基基团的氨基;Z 1、Z 2、Z 3、X 1、X 2、X 3、R 1、R 2、R a、R b、m和n的定义如权利要求1所述;情形4-3:R 3为H、卤素、羟基、氨基、硝基、氰基、羰基、氧代、羧基、C 1-C 6烷基、C 1-C 6氘代烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基、卤代C 1-C 6烷氧基;R 4和R 5各自独立地为氢、卤素、羟基、氨基、硝基、氰基、羰基、氧代、羧基、C 1-C 6烷基、C 1-C 6氘代烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基、卤代C 1-C 6烷氧基、C 1-C 6烷氧羰基、C 1-C 6烷基羰氧基、C 1-C 6烷氧基C 1-C 6烷基、C 1-C 6烷氧羰基C 1-C 6烷基、C 3-C 8环烷基、C 3-C 8环烷基羰基、C 3-C 8环烷氧基、任选具有1或2个C 1-C 6烷基基团的氨基羰基基团、C 1-C 6烷基磺酰基基团、任选具有1或2个C 1-C 6烷基基团的氨基磺酰基、C 1-C 6烷基磺酰基氨基基团或任选具有1或2个C 1-C 6烷基基团的氨基;Z 1、Z 2、Z 3、X 1、X 2、X 3、R 1、R 2、R a、R b、m和n的定义如权利要求1所述;方案5:所述的如式I所示的杂环类化合物为如下如式III-1、III-2、III-3、III-4、III-5、III-6、III-7、III-8所示结构:其中,Z 1、Z 2、Z 3、X 1、X 2、X 3、R 1、R 2、R 3、R 3-1、R a、R b、m和n的定义如权利要求1所述;方案6:所述的如式I所示的杂环类化合物为如下如式IV-1所示结构:式IV-1中各基团的定义为如下情形6-1或情形6-2:情形6-1:R 5-1为氢、卤素、羟基、氨基、硝基、氰基、羰基、氧代、羧基、C 1-C 6烷基、C 1-C 6氘代烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基、卤代C 1-C 6烷氧基、C 1-C 6烷氧羰基、C 1-C 6烷氧基C 1-C 6烷基、C 1-C 6烷氧羰基C 1-C 6烷基、C 3-C 8环烷基、C 3-C 8环烷基羰基、C 3-C 8环烷氧基、任选具有1或2个C 1-C 6烷基基团的氨基羰基基团、C 1-C 6烷基磺酰基基团、任选具有1或2个C 1-C 6烷基基团的氨基磺酰基、C 1-C 6烷基磺酰基氨基基团或任选具有1或2个C 1-C 6烷基基团的氨基;Z 1、Z 2、Z 3、X 1、X 2、X 3、R 1、R 2、R 3、R a、R b、m和n的定义如权利要求1所述;情形6-2:R 5-1选自氢、卤素、羟基、氨基、硝基、氰基、羰基、氧代、羧基、C 1-C 6烷基、C 1-C 6氘代烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基、卤代C 1-C 6烷氧基、C 1-C 6烷氧羰基、C 1-C 6烷基羰氧基、C 1-C 6烷氧基C 1-C 6烷基、C 1-C 6烷氧羰基C 1-C 6烷基、C 3-C 8环烷基、C 3-C 8环烷基羰基、C 3-C 8环烷氧基、任选具有1或2个C 1-C 6烷基基团的氨基羰基基团、C 1-C 6烷基磺酰基基团、C 1-C 6烷基磺酰基氨基基团或任选具有1或2个C 1-C 6烷基基团的氨基;Z 1、Z 2、Z 3、X 1、X 2、X 3、R 1、R 2、R 3、R a、R b、m和n的定义如权利要求1所述;方案7:所述的如式I所示的杂环类化合物为如下如式IV-2所示结构:式IV-2中各基团的定义为如下情形7-1或情形7-2:情形7-1:R 5-1为氢、卤素、羟基、氨基、硝基、氰基、羰基、氧代(=O)、羧基、C 1-C 6烷基、C 1-C 6氘代烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基、卤代C 1-C 6烷氧基、C 1-C 6烷氧羰基、C 1-C 6烷氧基C 1-C 6烷基、C 1-C 6烷氧羰基C 1-C 6烷基、C 3-C 8环烷基、C 3-C 8环烷基羰基、C 3-C 8环烷氧基、任选具有1或2个C 1-C 6烷基基团的氨基羰基基团、C 1-C 6烷基磺酰基基团、任选具有1或2个C 1-C 6烷基基团的氨基磺酰基、C 1-C 6烷基磺酰基氨基基团或任选具有1或2个C 1-C 6烷基基团的氨基;Z 1、Z 2、Z 3、X 1、X 2、X 3、R 1、R 2、R 3、R a、R b、m和n的定义如权利要求1所述;R 4不存在;情形7-2:R 5-1为氢、卤素、羟基、氨基、硝基、氰基、羰基、氧代、羧基、C 1-C 6烷基、C 1-C 6氘代烷基、C 2-C 6炔基、卤代C 1-C 6烷基、羟基C 1-C 6烷基、C 1-C 6烷基羰基、C 1-C 6烷氧基、卤代C 1-C 6烷氧基、C 1-C 6烷氧羰基、C 1-C 6烷基羰氧基、C 1-C 6烷氧基C 1-C 6烷基、C 1-C 6烷氧羰基C 1-C 6烷基、C 3-C 8环烷基、C 3-C 8环烷基羰基、C 3-C 8环烷氧基、C 1-C 6烷基磺酰基基团、任选具有1或2个C 1-C 6烷基基团的氨基磺酰基、C 1-C 6烷基磺酰基氨基基团或任选具有1或2个C 1-C 6烷基基团的氨基;Z 1、Z 2、Z 3、X 1、X 2、X 3、R 1、R 2、R 3、R a、R b、m和n的定义如权利要求1所述;R 4不存在。
- 如权利要求7所述的式I所示杂环类化合物、其溶剂化物、其药学上可接受的盐、其药学上可接受的盐的溶剂合物或其前药,其特征在于,所述的如式I所示的杂环类化合物选自下列任一化合物:或者,所述的如式I所示的杂环类化合物选自下列任一化合物:色谱柱:Chiralpak AD-3 50×4.6mm I.D.,3μm,流动相:流动相A:CO 2,流动相B:含有0.05体积%的二乙胺的异丙醇和乙腈的溶液;等度洗脱:50体积%的含有0.05体积%的二乙胺的异丙醇和乙腈的溶液在CO 2,流速:3mL/min;检测器:PDA,柱温:35℃;柱压:100Bar;色谱柱:Chiralpak AD-3 50×4.6mm I.D.,3μm,流动相:流动相A:CO 2,流动相B:含有0.05体积%的二乙胺的异丙醇和乙腈的溶液;等度洗脱:50体积%的含有0.05体积%的二乙胺的异丙醇和乙腈的溶液在CO 2,流速:3mL/min;检测器:PDA,柱温:35℃;柱压:100Bar;色谱柱:Chiralpak AS-3 50×4.6mm I.D.,3μm;流动相:流动相A:CO 2,流动相B:含有0.05体积%的二乙胺的异丙醇和乙腈的溶液;等度洗脱:40体积%的含有0.05体积%的二乙胺的异丙醇和乙腈的溶液在CO 2中;流速:3mL/min;检测器:PDA,柱温:35℃;柱压:100Bar;色谱柱:Chiralpak AS-3 50×4.6mm I.D.,3μm;流动相:流动相A:CO 2,流动相B:含有0.05体积%的二乙胺的异丙醇和乙腈的溶液;等度洗脱:40体积%的含有0.05体积%的二乙胺的异丙醇和乙腈的溶液在CO 2中;流速:3mL/min;检测器:PDA,柱温:35℃;柱压:100Bar;色谱柱:Chiralpak AD-3 50×4.6mm I.D.,3μm,流动相:流动相A:CO 2,流动相B:含有0.05体积%的二乙胺的异丙醇和乙腈的溶液;等度洗脱:50体积%的含有0.05体积%的二乙胺的异丙醇和乙腈的溶液在CO 2中,流速:3mL/min;检测器:PDA,柱温:35℃;柱压:100Bar;色谱柱:Chiralpak AD-3 50×4.6mm I.D.,3μm,流动相:流动相A:CO 2,流动相B:含有0.05体积%的二乙胺的异丙醇和乙腈的溶液;等度洗脱:50体积%的含有0.05体积%的二乙胺的异丙醇和乙腈的溶液在CO 2中,流速:3mL/min;检测器:PDA,柱温:35℃;柱压:100Bar;或者,所述的如式I所示的杂环类化合物选自下列任一化合物:
- 一种药物组合物,其特征在于,所述药物组合物包括:如权利要求1-8中任一所述的式I所示杂环类化合物、其溶剂化物、其药学上可接受的盐、其药学上可接受的盐的溶剂合物或其前药;和药学上可接受的载体。
- 一种物质的用途,其特征在于,所述的物质为如权利要求1-8中任一所述的式I所示杂环类化合物、其溶剂化物、其药学上可接受的盐、其药学上可接受的盐的溶剂合物、其前药或权利要求9所述的药物组合物;所述的用途为制备15-PGDH抑制剂、或、制备预防和/或治疗与15-PGDH相关的疾病的药物。
- 如权利要求10所述的用途,其特征在于,所述的与15-PGDH相关的疾病为纤维化疾病、炎性疾病、心血管疾病、创伤、自身免疫性疾病、移植物抗宿主疾病、毛发生长、骨质疏松症、耳病、眼病、中性白细胞减少、糖尿病、膀胱活动低下症、在干细胞或骨髓移植或器官移植中的植入物促进、神经发生和神经细胞死亡、血细胞重建、组织损伤、宫颈疾病或肾病中的一种、两种或更多种,优选为纤维化、炎性疾病或组织损伤中的一种或多种。
- 如权利要求11所述的用途,其特征在于,所述的纤维化疾病为肺纤维化、肝纤维化、肾纤维化、心肌纤维化、硬皮病或骨髓纤维化中的一种或多种,优选为肺纤维化和/或肝纤维化,例如肺纤维化;所述的肺纤维化优选为特发性肺纤维化;和/或,所述的炎性疾病为慢性阻塞性肺病、急性肺损伤、脓毒症、哮喘和肺病的恶化、炎症性肠病、消化性溃疡、自身炎性疾病、血管炎综合征、急性肝损伤、急性肾损伤、非酒精性脂肪肝、特应性皮炎、牛皮癣、间质性膀胱炎或前列腺炎综合征中的一种或多种,优选为炎症性肠病;所述的炎症性肠病优选为溃疡性结肠炎和/或克罗恩氏病;所述的消化性溃疡优选为NSAID诱导的溃疡;所述的自身炎性疾病优选为贝切特氏病;所述的前列腺炎综合征优选为慢性前列腺炎和/或慢性骨盆疼痛综合征;和/或,所述的心血管疾病为肺动脉高压、心绞痛、心肌梗死、心力衰竭、缺血性心脏病、脑卒中或周围循环紊乱中的一种或多种;和/或,所述的创伤为糖尿病性溃疡、烧伤、压迫性溃疡、急性粘膜损伤、包括斯-约二氏综合征、粘膜损伤、抗癌化疗剂有关的损伤、抗代谢物、细胞或体液免疫疗法或放射线有关的损伤中的一种或多种;所述的抗癌化疗剂优选为烷化剂、DNA合成抑制剂或DNA回旋酶抑制剂中的一种或多种;和/或,所述的自身免疫性疾病为多发性硬化和/或类风湿性关节炎;和/或,所述的耳病为听力损失、耳鸣、眩晕或平衡失调中的一种或多种;和/或,所述的眼病为青光眼和/或干眼;和/或,所述的神经发生和神经细胞死亡为精神神经疾病、神经病、神经毒性疾病、神经性疼痛或神经变性疾病中的一种或多种;和/或,所述的组织损伤为肝损伤和/或肌肉损伤;所述肌肉损伤优选为肌肉萎缩和/或肌营养不良;和/或,所述的肾病为慢性肾病和/或肾衰竭。
- 如权利要求10所述的用途,其特征在于,所述的预防和/或治疗与15-PGDH相关的疾病为预防和/或治疗肝脏再生。
- 一种如权利要求1-8中任一所述的式I所示杂环类化合物、其溶剂化物、其药学上可接受的 盐、其药学上可接受的盐的溶剂合物、其前药或权利要求9所述的药物组合物的用途,其特征在于,所述的用途为用于制备预防或治疗疾病的药物;所述的疾病为纤维化疾病、炎性疾病或组织损伤中的一种或多种;优选,所述的纤维化疾病、所述的炎性疾病和所述的组织损伤均如权利要求12所述。
- 一种抑制15-PGDH或预防或治疗疾病的方法,其特征在于,包括步骤:给需要的对象施用如权利要求1-8中任一所述的式I所示杂环类化合物、其溶剂化物、其药学上可接受的盐、其药学上可接受的盐的溶剂合物、其前药或权利要求9所述的药物组合物;所述的疾病为与15-PGDH相关的疾病、纤维化疾病、炎性疾病或组织损伤中的一种或多种;优选,所述的与15-PGDH相关的疾病如权利要求12所述;所述的纤维化疾病、所述的炎性疾病和所述的组织损伤均如权利要求10-13中任一项所述。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022392348A AU2022392348A1 (en) | 2021-11-18 | 2022-11-18 | 15-pgdh inhibitor and use thereof |
CA3238595A CA3238595A1 (en) | 2021-11-18 | 2022-11-18 | 15-pgdh inhibitor and use thereof |
IL312896A IL312896A (en) | 2021-11-18 | 2022-11-18 | 15-PGDH inhibitor and its use |
KR1020247020064A KR20240107333A (ko) | 2021-11-18 | 2022-11-18 | 15-pgdh 억제제 및 용도 |
EP22894954.1A EP4434986A1 (en) | 2021-11-18 | 2022-11-18 | 15-pgdh inhibitor and use thereof |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111372073.X | 2021-11-18 | ||
CN202111372073 | 2021-11-18 | ||
CN202210837015 | 2022-07-15 | ||
CN202210837015.8 | 2022-07-15 | ||
CN202211408212 | 2022-11-10 | ||
CN202211408212.4 | 2022-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023088425A1 true WO2023088425A1 (zh) | 2023-05-25 |
Family
ID=86334445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/132863 WO2023088425A1 (zh) | 2021-11-18 | 2022-11-18 | 15-pgdh抑制剂及用途 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4434986A1 (zh) |
KR (1) | KR20240107333A (zh) |
CN (1) | CN116135856A (zh) |
AU (1) | AU2022392348A1 (zh) |
CA (1) | CA3238595A1 (zh) |
IL (1) | IL312896A (zh) |
TW (1) | TW202325292A (zh) |
WO (1) | WO2023088425A1 (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020145250A1 (ja) | 2019-01-08 | 2020-07-16 | 杏林製薬株式会社 | 15-pgdh阻害薬 |
WO2020160151A1 (en) * | 2019-01-31 | 2020-08-06 | Kyorin Pharmaceutical Co., Ltd. | 15-pgdh inhibitors |
WO2021016333A1 (en) | 2019-07-22 | 2021-01-28 | University Of Hawaii | Aryl sulfonamides as small molecule stat3 inhibitors |
WO2021151014A1 (en) * | 2020-01-23 | 2021-07-29 | Myoforte Therapeutics, Inc. | Pgdh inhibitors and methods of making and using |
-
2022
- 2022-11-18 CN CN202211449273.5A patent/CN116135856A/zh active Pending
- 2022-11-18 CA CA3238595A patent/CA3238595A1/en active Pending
- 2022-11-18 TW TW111144257A patent/TW202325292A/zh unknown
- 2022-11-18 IL IL312896A patent/IL312896A/en unknown
- 2022-11-18 KR KR1020247020064A patent/KR20240107333A/ko unknown
- 2022-11-18 AU AU2022392348A patent/AU2022392348A1/en active Pending
- 2022-11-18 EP EP22894954.1A patent/EP4434986A1/en active Pending
- 2022-11-18 WO PCT/CN2022/132863 patent/WO2023088425A1/zh active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020145250A1 (ja) | 2019-01-08 | 2020-07-16 | 杏林製薬株式会社 | 15-pgdh阻害薬 |
CN113226310A (zh) * | 2019-01-08 | 2021-08-06 | 杏林制药株式会社 | 15-pgdh抑制剂 |
WO2020160151A1 (en) * | 2019-01-31 | 2020-08-06 | Kyorin Pharmaceutical Co., Ltd. | 15-pgdh inhibitors |
WO2021016333A1 (en) | 2019-07-22 | 2021-01-28 | University Of Hawaii | Aryl sulfonamides as small molecule stat3 inhibitors |
WO2021151014A1 (en) * | 2020-01-23 | 2021-07-29 | Myoforte Therapeutics, Inc. | Pgdh inhibitors and methods of making and using |
Non-Patent Citations (1)
Title |
---|
DAMIEN Y. DUVEAU, ADAM YASGAR, YUHONG WANG, XIN HU, JENNIFER KOUZNETSOVA, KYLE R. BRIMACOMBE, AJIT JADHAV, ANTON SIMEONOV, CRAIG J: "Structure–activity relationship studies and biological characterization of human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 24, no. 2, 1 January 2014 (2014-01-01), Amsterdam NL , pages 630 - 635, XP055348274, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2013.11.081 * |
Also Published As
Publication number | Publication date |
---|---|
TW202325292A (zh) | 2023-07-01 |
CA3238595A1 (en) | 2023-05-25 |
KR20240107333A (ko) | 2024-07-09 |
EP4434986A1 (en) | 2024-09-25 |
CN116135856A (zh) | 2023-05-19 |
IL312896A (en) | 2024-07-01 |
AU2022392348A1 (en) | 2024-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106458934B (zh) | 喹喔啉化合物及其用途 | |
WO2018166493A1 (zh) | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 | |
TWI834795B (zh) | 15-pgdh抑制劑 | |
TWI683811B (zh) | 二氫噠嗪-3,5-二酮衍生物 | |
WO2021190417A1 (zh) | 新型氨基嘧啶类egfr抑制剂 | |
JPH11503758A (ja) | 血小板活性化因子拮抗物質としてのインドール−3−カルボニル及びインドール−3−スルホニル誘導体 | |
CN114728962A (zh) | 血浆激肽释放酶抑制剂及其用途 | |
US20160333007A1 (en) | Heteroaryls and uses thereof | |
JP2023539136A (ja) | Tlr9阻害剤として有用な置換ヘテロアリール化合物 | |
WO2022017408A1 (zh) | 芳胺类衍生物及其制备方法和医药用途 | |
CN112601745A (zh) | 一种氮杂芳基酰胺衍生物及其制备方法和应用 | |
WO2023088425A1 (zh) | 15-pgdh抑制剂及用途 | |
WO2023280254A1 (zh) | 一种tead抑制剂 | |
WO2022222911A1 (zh) | 嘧啶酮化合物及其用途 | |
CN107428682B (zh) | 酰胺类衍生物、其制备方法及其在医药上的用途 | |
WO2022228515A1 (zh) | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 | |
CN107001360B (zh) | 4H-吡啶并[1,2-a]嘧啶-4-酮化合物 | |
WO2024041589A1 (zh) | 含氮杂环化合物、其制备方法、其中间体及其应用 | |
WO2023078461A1 (zh) | 杂环类化合物及其制备方法和用途 | |
WO2023078241A1 (zh) | 芳胺类衍生物及其制备方法和医药用途 | |
WO2023125121A1 (zh) | 一类三并环化合物、其制备方法及用途 | |
WO2024104322A1 (zh) | 15-pgdh抑制剂 | |
WO2023246837A1 (zh) | 一类具有嘧啶并六元环结构的化合物、包含其的药物组合物及其应用 | |
WO2022161420A1 (zh) | 一类芳杂环类化合物及其制备方法和用途 | |
CN107759522B (zh) | 羧酸类衍生物、其制备方法及其在医药上的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22894954 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2024529715 Country of ref document: JP Kind code of ref document: A Ref document number: 3238595 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024009877 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202447042553 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20247020064 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202491286 Country of ref document: EA Ref document number: 2022392348 Country of ref document: AU Ref document number: 1020247020064 Country of ref document: KR Ref document number: AU2022392348 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022894954 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022894954 Country of ref document: EP Effective date: 20240618 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11202403338P Country of ref document: SG |
|
ENP | Entry into the national phase |
Ref document number: 112024009877 Country of ref document: BR Kind code of ref document: A2 Effective date: 20240517 |